ANTI-INFECTIOUS PYRIMIDINE AND USES OF IT

Crystal forms

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4.

Secure computer-implemented execution and evaluation of programming assignments for on demand courses

In one general aspect, a computer-implemented method can include receiving, by a computer system, code for a custom grader application, creating, by the computer system, a base custom grader container including the code for the custom grader application, associating the base custom grader container with an online course included in a repository included in the computer system, evaluating, by the computer system, the base custom grader container by executing the custom grader application in the base custom grader container, determining that the custom grader application violates a predetermined criterion, modifying the base custom grader container to prevent the executing of the custom grader application from violating the predetermined criterion, and storing, in the repository and in association with the online course, the modified base custom grader container including the custom grader application as a custom grader container image.

Device and method for analyzing and measuring quality of TD-HSUPA signals

The invention discloses a device and a method for analyzing and measuring the quality of TD-HSUPA signals. The device comprises a measuring signal receiving unit, a DDC conversion unit, a time slot synchronization unit, a frequency error computing and eliminating unit, a signal descrambling and de-spreading unit, a reference code channel signal recovery unit and an IQ reference HSUPA signal recovery unit. A TD-HSUPA measuring signal transmitted by a terminal is processed orderly by the units, and finally, a modulation domain measuring unit and a code domain measuring unit are utilized to compute an error vector amplitude value and a code domain power value. The device analyzes and measures the measuring signal output from the terminal, so that not only demodulation signals with high quality and low bit error rate are transmitted to a physical layer of a base station, but also a frequency error and the error vector amplitude value of the measuring signal are measured.

AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES

A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt. 12. Compound of claim 11 , which is (3R claim 11 ,4s claim 11 ,5S claim 11 ,7s)-1-azaadamantan-4-yl formate.13. Compound of claim 11 , which is (3R claim 11 ,4r claim 11 ,5S claim 11 ,7s)-1-azaadamantan-4-yl formate.15. Process of claim 14 , wherein the isomerizing agent is potassium tert-butoxide.16. A process for preparing a 2-amino-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole salt claim 14 , the process comprising step of contacting aminothiourea and benzoic acid in presence of polyphosphoric acid.18. A process for preparing 2-bromo-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole claim 14 , or salt or solvate thereof claim 14 , the process comprising step of contacting a 2-amino-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole salt claim 14 , a Cu(II)halide and an alkyl-nitrite claim 14 , in presence of a polar aprotic solvent.20. A process for preparing 2-bromo-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole claim 14 , or salt or solvate thereof claim 14 , the process comprising steps of:(a) contacting aminothiourea and benzoic acid in presence of polyphosphoric acid to form a 2-amino-5-phenyl-1,3,4-thiadiazole salt; and(b) contacting the 2-amino-5-phenyl-1,3,4-thiadiazole salt, a Cu(II)halide and an alkyl-nitrite, in presence of a polar aprotic solvent.2226-. (canceled) Azaadamantane derivatives and a process for preparing azaadamantane derivatives are described. More particularly, azaadamantane formate ester intermediate is described. Additionally, processes for preparing the azaadamantane formate ester ...

PARTICLE SENSOR AND PARTICLE SENSING METHOD

A particle sensing apparatus is provided for determining particle concentration in a fluid, e.g. air. The apparatus is based on fluid-flow passageway having an upstream inlet to receive the fluid and a downstream outlet to exhaust the fluid. It also includes a recirculation passageway in fluid communication with the fluid-flow passageway. Between them, the fluid-flow passageway and the recirculation passageway define a recirculation loop. A first particle sensor is located in the recirculation loop, and other sensors may also be present at other options. A force applicator is included in the fluid-flow passageway to apply a force to the particles entrained in the fluid. The force is used to direct some or all of the particles into the recirculation loop. This provides a choice between increasing the detection limit or the detection range. A processor determines the concentration of particles in the fluid based on the concentration of particles detected at the first particle sensor. 1. A particle sensing apparatus for determining particle concentration in a fluid comprising:a fluid-flow passageway having an upstream inlet to receive the fluid and a downstream outlet to exhaust the fluid;{'b': '14', 'a recirculation passageway in fluid communication with the fluid-flow passageway, where a portion of the fluid-flow passageway () and the recirculation passageway define a recirculation loop;'}a flow control arrangement for generating a flow of said fluid between the upstream inlet and the downstream outlet and around the recirculation loop;a first particle sensor located in the recirculation loop;a force applicator to apply a force to the particles entrained in the fluid such that the particles move relative to said flow, the force applicator being arranged to control the passage of the particles either into the recirculation loop or to the downstream outlet; anda processor adapted to determine the concentration of particles in the fluid based on the concentration of ...

Protein tyrosine phosphatase inhibitors and methods of use thereof

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

System, method, uses, products, program products, and business methods for distributed internet and distributed network services

A method and system for functioning within the field of distributing networks, web and server applications, systems, subsystems, applications, sub-applications, components, modules, functions, over one or more computer networks. A method and system for deploying and/or adjusting and/or transmitting and/or receiving digital assets and otherwise in a multi-tiered network.

Crystalline forms of rapamycin analogs

A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I) ...

Uracil or thymine derivative for treating hepatitis C

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Catalyst for ethanol vapor-phase carbonyl synthesis for diethyl carbonate and its preparation method

Fixed-wing composite four-rotor aircraft

The utility model provides a fixed-wing composite four-rotor aircraft. Aircraft comprising an aircraft body, the aircraft body comprises a fuselage provided with a control center. Fixed wings are arranged on the two opposite sides of the vehicle body, and vehicle arms are arranged at the ends, away from the vehicle body, of the fixed wings. Propellers are arranged at the two ends of the vehicle arms; a flap is hinged to one side of the fixed wing; a connecting column is fixedly arranged on the bottom face of the flap, a steering engine is arranged in the fixed wing, the output end of the steering engine is connected with a rudder angle rotating shaft, a connecting rod is arranged between the rudder angle rotating shaft and the connecting column, the two ends of the connecting rod are hinged to the rudder angle rotating shaft and the connecting column respectively, and a through hole is formed in the lower end face of the fixed wing for the rudder angle rotating shaft to penetrate. Thefixed-wing ...

Mulberry picking method and device capable of intelligently identifying maturity based on machine vision

The invention relates to the field of automatic mulberry picking, and particularly discloses a mulberry picking method and device capable of intelligently recognizing maturity based on machine vision. Mulberries in an orchard are grouped before picking, mulberry images corresponding to each group of mulberries are collected, color features and area features of the mulberries are extracted in combination with an image processing technology, and maturity detection is performed on the pre-grouped mulberries by using a pre-trained multi-layer perceptron maturity detection model. According to the method, the picking task of the mulberries is selected, vibration picking parameters are set for the multiple vibration picking devices participating in the picking task based on different maturity, then the whole picking task is distributed and planned, finally the mulberry picking efficiency and quality are improved, and damage to the mulberries in the picking process is reduced.

Video conference processing method and device, electronic equipment and storage medium

The embodiment of the invention provides a video conference processing method and device, and the method comprises the steps: responding to a conference creation operation of a first user of first terminal equipment, and generating a virtual object and conference invitation information of a target video conference; and pushing the conference invitation information to a second terminal device by using the virtual object, so that the second terminal device adds a second user to the target video conference in response to conference joining response operation of the second user for the conference invitation information. According to the embodiment of the invention, the conference invitation information is prevented from being directly sent through a mail or other instant messaging software, the risk that the conference invitation information is leaked in the sending process is reduced, and the security of the video conference is improved. The encrypted conference joining request generated by ...

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Stacked City Road

A three-dimensional urban road system capable of intensively utilizing land and avoiding traffic jam is provided, including a straight section, a longitudinal slope section and an intersection. The straight section and the intersection are connected to form a road network. The longitudinal slope section is connected with the straight section, realizing connection between the straight section and the ground. The straight section includes a bottom road, a parking layer and a running layer; parallel ramps for small cars only arranged such that small cars in the straight section can switch among the three layers. Roads are changed into three layers: the upper running layer for small cars; the middle parking layer, a transfer layer for parking and connecting the ground road and the upper running layer; and the bottom road for large vehicles. Large vehicles and small cars are completely shunted, thus effectively solving the problem of traffic jam.

CRYSTAL FORMS

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. - 18-. (canceled)10. The process of claim 9 , wherein the solution further comprises an excipient.11. The process of claim 9 , wherein the solution further comprises a surfactant.12. The process of claim 9 , further comprising spray drying the solution claim 9 , thereby forming a solid dispersion.13. The process of claim 10 , further comprising spray drying the solution claim 10 , thereby forming a solid dispersion.14. The process of claim 11 , further comprising spray drying the solution claim 11 , thereby forming a solid dispersion.15. The process of claim 9 , further comprising freeze drying the solution claim 9 , thereby forming a solid dispersion.16. The process of claim 10 , further comprising freeze drying the solution claim 10 , thereby forming a solid dispersion.17. The process of claim 11 , further comprising freeze drying the solution claim 11 , thereby forming a solid dispersion.19. The method of claim 18 , wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (°2θ) of 8.4 claim 18 , 8.9 claim 18 , 10.2 claim 18 , 11.1 claim 18 , 12.2 claim 18 , 12.5 claim 18 , 13.2 claim 18 , 13.7 claim 18 , 14.5 claim 18 , 15 claim 18 , 15.5 claim 18 , 15.9 claim 18 , 17.4 claim 18 , 17.8 claim 18 , 19.6 claim 18 , 19.9 claim 18 , 21.1 claim 18 , 22.2 claim 18 , 22.7 claim 18 , and 23.9.20. The method of claim 19 , wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (°2θ) of 6.7 claim 19 , 8.4 claim 19 , 8.9 claim 19 , 9.9 claim 19 , 10.2 claim 19 , 11.1 claim 19 , 12.2 claim 19 , 12.5 claim 19 , 13.2 claim 19 , 13.7 claim 19 , 14.5 claim 19 , 15 claim 19 , 15.5 claim 19 , 15.9 claim 19 , 17.4 claim 19 , 17.8 claim 19 , 18.1 claim 19 , 18.9 claim 19 , 19 claim 19 , 19.6 claim 19 , 19.9 claim 19 ...

WIRELESS EARPHONE

A wireless earphone comprising an in-ear portion which is in contact with a human ear when the wireless earphone is worn. The in-ear portion comprises a wearing surface which couples the human ear canal when the wireless earphone is worn. The in-ear portion is provided with a wearing detection sensor, a sound venting hole and a contact group which are all disposed on the wearing surface. The wearing detection sensor, the sound venting hole and the contact group are all disposed on the wearing surface of the in-ear portion coupling the human ear canal, so that the wearing detection sensor can directly contact the skin of the human body when the earphone is worn, and thus the wearing detection sensor is improved.

SPLIT-TYPE PISTON HAVING ADDITIONAL AIR CHAMBER AND AIR SPRING

The present disclosure provides a split-type piston having additional air chamber, and an air spring adopting the split-type piston having additional air chamber. The split-type piston includes a piston body and an upper end cover connected to the piston body by threaded connection; a sealed additional air chamber is defined between the piston body and the upper end cover.

Hemostatic compositions and methods of making thereof

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.

Tobacco curing room with hot air internal circulation

The invention discloses a tobacco curing room with hot air internal circulation, which comprises walls and a ceiling fixedly arranged on the walls. A plurality of upper hot air raising channels are arranged in the ceiling with a closed upper end; the upper ends of the upper hot air raising channels are open; the lower ends of the upper hot air raising channels are communicated with lower hot air raising channels arranged in the walls; inlet opening/closing valves are arranged on the lower hot air raising channels; the ceiling consists of a plurality of double-layer insulated blocks with cavity insulated layers; two sides of each double-layer insulated block are provided with vents; and the cavity insulated layers of the longitudinal double-layer insulated blocks of the ceiling are communicated through the vents to form the plurality of upper hot air raising channels. The tobacco curing room with hot air internal circulation has the advantages of simple structure and low manufacturing cost ...

Automatic water-spraying fire extinguishing device for fire fighting and use method of automatic water-spraying fire extinguishing device

The automatic water spraying fire extinguishing device comprises a supporting base and a water spraying guide pipe installed on the supporting base, a water source connecting pipe is arranged on one side of the top of the water spraying guide pipe, installation bases are arranged on the two sides of the supporting base, a liquid distribution disc is arranged at the bottom of the water spraying guide pipe, and a supporting frame is arranged at the edge of the bottom of the liquid distribution disc; according to the automatic water spraying and fire extinguishing device for fire fighting and the using method thereof, through cooperation between a second transmission shaft and a sleeve block, a plurality of spraying heads slightly rotate leftwards and rightwards to spray and extinguish fire, meanwhile, a first transmission shaft and a rotating disc are matched, rotation of a stirring block triggers rotation of a rotating assembly, and under the elastic force effect of a reset spring, the automatic ...

AS INHIBITORS OF THE HEPATITIS C VIRUS (HCV) APTITUDE N-PHENYLDIOXOHYDROPYRIMIDINE ONE

Uracil or thymine derivative for treating hepatitis C

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4- thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

Detection method of shallow interface between volcanic rock and granite

The invention relates to a detection method of the shallow interface between volcanic rock and granite. The method sequentially comprises the following steps that firstly, nearby the insidious interface between the volcanic rock and the granite, the velocity of longitudinal waves and the velocity of transverse waves are obtained through seismic waves generated due to excitation of an artificial seismic source; secondly, a first parameter, a second parameter and a Poisson ratio parameter are obtained, wherein the first parameter is a difference between the square of the velocity of the longitudinal waves and the square of the double velocity of the transverse waves, the second parameter is a difference between the square of the double velocity of the longitudinal waves and the square of the velocity of the transverse waves, and the Poisson ratio parameter is obtained by dividing the first parameter by the second parameter; thirdly, a Poisson ratio parameter low-value range from 0.10 to 0.23 ...

MONOHYDRATE OF AZA-ADAMANTANO DERIVATIVES

Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.Reivindicación 1: Una forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, caracterizada porque el (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano está representada por la fórmula (1) y en donde el citrato diácido está representado por la fórmula (2).

Server system and method for exporting digital assets in enterprise information systems

Member objects of a computer system part(s) in an Enterprise Information System (EIS) are identified and categorized for export to a packaging process or to another computer system over tiers of network(s). An intermediate representation of the part(s) is made while applying context rule(s) to determine a standard specified context or a non-specified context of the parts. For a standard specified context, a directed search acquires the set of runnable and/or non-runnable member objects in a location(s) in the EIS. For a non-specified context, an implicit traversal search is performed for any of the set of runnable and/or non-runnable member objects in one or more locations in an Enterprise Information System (EIS). Set(s) of runnable and/or non-runnable member objects are accessed at their locations in the EIS and a preliminary package specification is made therefrom. Digital assets listed therein are updated with export descriptors added to the extended environment.

Server system and method for discovering digital assets in enterprise information systems

Member object(s) of a computer system part(s) in an Enterprise Information System (EIS) are identified (discovered) and topographical relationship(s) are established among them to create digital assets by traversing computer file system(s) to find member object(s). For each member object found, a digital asset identifier thereof is placed in an intermediate representation, such as a graph with nodes and edges. Each digital asset identifier corresponds to a node. The edges represent the topographical relationship. A digital asset is created by placing the member object in a logic/data section of the digital asset, attaching an extended environment data structure to the logic/data section and storing the digital asset in an asset inventory container object. This is repeated for each found member object until the intermediate representation fully describes the computer system part and the asset inventory container object is a complete inventory of the digital assets in the computer system part. 1. A discovery method for identifying member objects of one or more computer system parts in an Enterprise Information System (EIS) and for establishing at least one topographical relationship among the member objects , the discovery method being executable by one or more computers , each of the computers having one or more memories and one or more central processing units (CPU) , the method comprising the steps of:a. traversing one or more computer file systems of the EIS to find one or more of the member objects, the member objects meeting one or more selection criteria;b. for each member object found, placing a digital asset identifier of the member object in an intermediate representation, the intermediate representation being a graph with nodes and edges, each of the digital asset identifiers corresponding to one of the nodes of the graph, the edges representing the topographical relationship;c. creating a digital asset from the member object by placing the member object in ...

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Uracil or thymine derivative for treating hepatitis C

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

CRYSTAL FORMS

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4.

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

Catalyst for synthesizing diethyl carbonate by ethanol vapor-phase carbonyl

Novel method for synthesizing prulifloxacin

The invention relates to a method for synthesizing prulifloxacin of formula (I) with a chemical name of 6-fluoro-1-methyl-7-[4-(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylicacid. The method for synthesizing prulifloxacin is suitable for industrial production and has the advantages of simple process, high purity and high yield.

Root system reinforcing structure of true and false mixed lawn

The utility model discloses a true and false mixed lawn root system reinforcing structure, which belongs to the field of lawn paving equipment and comprises a lawn body, a groove is arranged at the top of the lawn body, an artificial lawn plate is mounted in the groove, a cavity is arranged in the artificial lawn plate, a rotating rod and a silk cluster which are vertically arranged are mounted on the artificial lawn plate, and the silk cluster is arranged in the groove. The bottom end of the rotating rod is sleeved with a second gear, a plurality of vertically-arranged stand columns are rotationally installed on the inner bottom wall of the cavity, the stand columns are sleeved with first gears, the first gears are meshed with one another, the second gear is meshed with the first gears, a horizontally-arranged transverse plate is rotationally installed at the top ends of the stand columns, and two vertically-arranged clamping blocks are slidably installed at the top of the transverse plate ...

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.Figure 1 ...

MODULAR FLUID SENSING SYSTEM

The invention describes a modular fluid sensing system comprising a fluid sensing terminal (150) and removable fluid channel units (101, 102, 103). The fluid channel units (101, 102, 103) comprise or can be combined with fluid treatment units as filters, sensors and seals. The fluid channel units (101, 102, 103) can be combined in accordance with the present needs of the user of the fluid sensing system. The invention therefore enables a reconfigurable channel system with reconfigurable measurement and treatment options within a fluid sensing system.

Uracil or thymine derivative for treating hepatitis C

Uracil or thymine derivative for treating hepatitis C

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4 dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E) N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl phenyl)methanesulfonamide.

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Circuit capable of enlarging dynamic range of analog-digital conversion

The invention relates to a circuit capable of enlarging a dynamic range of analog-digital conversion, wherein a coupler is connected with a gain rule judging circuit and a first intermediate frequency amplifier, the first intermediate frequency amplifier is connected with a controllable gain attenuator, a second intermediate frequency amplifier, an analog-digital conversion module and a control module in sequence, and the control module is connected with the controllable gain attenuator and the gain rule judging circuit. By means of the circuit capable of enlarging the dynamic range of analog-digital conversion, by tracing the power of an intermediate frequency signal, the attenuation value of the controllable gain attenuator is controlled by the control module, so that the gain of the intermediate frequency signal is changed, and by processing the sampling value of the analog-digital conversion module at corresponding moments through an algorithm in the control module, under the condition ...

Quality control design method for hydraulic generators

The invention discloses a quality control design method for hydraulic generators. The technical scheme includes that variables greatly affects electromagnetic design of the hydraulic generators are selected as variables to be optimally designed according to working conditions of the hydraulic generators at multiple different power points except rated power points, sensibility of motor performance indexes to design parameter changes and actual conditions such as processing and assembling technology, operational working environment and component deterioration and wear of the hydraulic generators, multi-index quality control design models are created for design objectives such as rated operating efficiency, weighted average efficiency and production cost of the hydraulic generators and performance constraints such as short-circuit ratios and reactance guarantee values of the hydraulic generators by the Taguchi method, and finally, the hydraulic generators which are stable in performance, reliable ...

Recombinant human interferon alpha nebula

The invention provides an interferon spray formulation for the prevention and the treatment of human upper respiratory tract virus infection. The formulation of the invention is prepared by combining the recombined interferon raw liquor with adequate protective agent, mucosa absorbent promoter and bacteria inhibiting agent. PH value varies from 5.0 to 8.0. The indications of the formulation are influenza, viral pneumonia and other respiratory virus infection disease.

Overhead ground wire grounding detection system

The invention provides an overhead ground wire grounding detection system. The system comprises a power supply module, a DC boost module, an inverter module, a first filtering module, a second filtering module, a coupling loading unit, a control transmission module and an acquisition unit. The output end of the power supply module is connected to the input end of the direct current boosting module, the output end of the direct current boosting module is connected to the input end of the inversion module through the first filtering module, and the output end of the inversion module is connected to the input end of the second filtering module. The output end of the second filtering module is connected to the input end of the coupling loading unit, and the coupling loading module loads test voltage to the overhead ground wire through electromagnetic induction; the acquisition unit is used for acquiring voltage and current of the overhead ground wire and outputting the voltage and current to ...

System, method, uses, products, program products, and business methods for distributed internet and distributed network services

Monohydrate of an azaadamantane derivative

The invention relates to a crystalline monohydrate of ( ...

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

KIOSK AND SERVER CONNECTED TO COMPUTER NETWORK

A server system (195) is connected to a plurality of kiosks (100) by a network (150), e.g., the Internet, corporate or government intranets, extranets, etc. A kiosk has one or more predetermined input/output devices (130) (e.g. displays, keyboards, paper printers, telephones, etc.) and one or more driver programs (110) (local APIs) for each of the input/output devices (130). The displays (103) are used to present one or more graphical user interfaces (105) and video images to a user of the kiosk (100). The kiosk (100) has a browser (160) which it uses to obtain material from the server (195). The server (195) has one or more application files (175) or configuration sets that it serves to the kiosks (100). The configuration sets are application specific (an application is a use for which the kiosks are configured or reconfigured). One or more of the files in the configuration sets include one or more embedded control programs that are used to control the local APIs for the devices on the kiosk. In this way, the devices are controlled to configure the kiosk to perform the application.

METHOD OF MAKING HEMOSTATIC COMPOSITIONS

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

N-PHENYL-DIOXO-HYDRO PYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITOR

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I) ...

N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I) ...

Rice hull-based polyurethane adhesive containing rice husk-based polyhydric alcohols, and preparation method thereof

The invention relates to a method used for synthesizing high-molecular materials from biomass, and specifically discloses a rice hull-based polyurethane adhesive containing rice husk-based polyhydric alcohols and a preparation method thereof. According to the preparation method, rice hull powder is subjected to liquidation under certain conditions so as to prepare the rice husk-based polyhydric alcohols; the rice husk-based polyhydric alcohols, polyester polyols, and isocyanate are taken as raw materials, dioxane is taken as a solvent, in the presence of catalyst dibutyltin dilaurate, a polyurethane prepolymer is prepared; and then a small molecule chain extender is added for chain extension so as to obtain the polyurethane adhesive emulsion. Full utilization of rice hull resource which is cheap, easily available, and renewable is realized; dependence on fossil resource is relieved; operation is simple and is convenient to control; the obtained rice hull-based polyurethane adhesive emulsion ...

Optical signal to noise ratio measuring method

The invention relates to an optical signal to noise ratio measuring method. The method comprises the following steps: measuring the to-be-measured spectrum of an optical signal at the to-be-measured point of an optical transmission line, and acquiring the comparison spectrum of the optical signal at a signal to noise ratio different from the to-be-measured point within a channel wavelength range; integrating the to-be-measured spectrum and the comparison spectrum respectively within the channel wavelength range of the optical signal to obtain a total power P to-be-measured spectrum and a P comparison spectrum, and acquiring a noise figure F and a signal scaling factor A; calculating a noise power N to-be-measured spectrum within the channel wavelength range of the optical signal in the to-be-measured spectrum according to the total power, the noise figure and the signal scaling factor in order to calculate the optical signal to noise ratio at the to-be-measured point. The optical signal ...

System and method for distributing assets to multi-tiered network nodes

Provided are methods and systems for distributing an asset to a multi-tiered network node. A pending notice is received from a distribution server. If the notice indicates that at least one asset is pending, i.e., awaiting deployment, an asset descriptor manifest is received from the distribution server. The asset descriptor manifest, which is stored in a memory on a node, identifies at least one asset to be deployed to the node and includes an offset associated with the asset identifier. A fragment, associated with the asset, is received and stored in the memory. The offset associated with the asset is marked with the end of the fragment and a second fragment, beginning at the offset, is received. Additional fragments are received, and the offset updated, until the entire asset is deployed to the node. Alternately, the entire asset or multiple assets are received in the first fragment.

AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES

A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt.

System and method for collaboration using web browsers

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Backlight module group and its cable immobilizing structure

The invention provides a cable fixed structure for a backlight module, comprising a body and a plurality of buckle parts, wherein, the body is provided with cable receiving conduits for receiving cables, the inner wall of each receiving conduit is provided with a stop block, the plurality of buckle parts are arranged on two sides of the body and are clamped on one back plate of the backlight module, thereby preventing the cables from falling off from the inside of the cable receiving conduits and preventing the cable from pulling welded points at tail ends of the cables due to overmuch movement.

Method for preparing succinic acid based on alloy wire mesh-bipolar film combined electrode technology

The invention relates to the field of electrochemical synthesis, in particular to design of an anode in an electrolytic bath and a method for preparing succinic acid based on an alloy wire mesh-bipolar film combined electrode technology. In the invention, an alloy wire mesh is used as an anode and is attached to a bipolar film closely to prepare an alloy wire mesh-bipolar film combined electrode;by compressing the space of an anode chamber to zero, zero-polar distance electrolysis is realized and mass transfer impedance in the anode chamber is greatly reduced, thus the voltage of the electrolytic bath is reduced and the effect of energy saving is achieved. In the invention, by using the principle that the bipolar film dissociates water under the action of an electric filed, hydrogen ionsand hydroxyl ions generated after water dissociation are respectively led into a cathode chamber and the anode chamber for adjusting the pH value of a reaction medium; in the production process of succinic ...

And access control device is used for protecting charging module in charging pile

The utility model discloses an access control device for protecting a charging module in a charging pile. The charging pile comprises a charging pile body, the charging pile body is provided with a client display terminal, a safety terminal and an alarm terminal. The client display terminal comprises a liquid crystal display screen, an IC card recognizer and an instruction input device. The instruction input device is connected with the LCD; the IC card recognizer is connected with the liquid crystal display screen; the safety end is a safety box, the alarm end is connected with the client display end, and the alarm end is connected with the safety box. By using the access control device, the good effects of protecting the charging module, preventing mistaken touch, ensuring the power utilization safety of a user and giving an alarm to remind a manager and the user in case of an accident can be achieved.

MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4- thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS

Filter element and gas purification device comprising a filter element

A filter element (1) for use in a gas purification device (100) is disclosed. It comprises a substrate (10) and a filter layer (20) covering an exterior surface of the substrate (10). The substrate (10) comprises material for containing chemicals (30) effective to remove gas pollutants from a gas. The material of the filter layer (20) is hydrophilic to adsorb liquid solution adsorbents effective in removing gas pollutants from a gas, and the exterior surface of the substrate (10) covered by the filter layer (20) is hydrophobic.

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS

The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Programme -controlled reputation spectral detection system gains based on variable OSK radio frequency modulation

The utility model discloses a programme -controlled reputation spectral detection system gains based on variable OSK radio frequency modulation, leading light path shares to AOTF according to its electric tuning characteristic, utilizes AD9910's OSK function to carry out the OSK modulation to its synthetic radiofrequency signal for dividing the optical element, through a plurality of AOTF of radio -frequency relay timesharing drive, realizes single spectral signature electrical modulation, the detector of rearmounted corresponding spectral coverage is put before and, utilizes the analog channel selector to correspond the gating, and the sharing simulation spectral signature handle and acquisition circuit, through to the OSK modulating signal digital phase shift, and phase shift that compensation measured signal produced in the circuit, then carry out the cross -correlation phase locking with measured signal, voltage -controlled amplifier is cascaded with programmable amplifier in the system ...

Method for processing passenger ticket information of high-speed railways

The invention provides a method for processing passenger ticket information of high-speed railways, which comprises the following steps: according to a service flow and a service rule for the passenger ticket of the high-speed railways, analyzing the passenger ticket information, thereby acquiring an original secondary passenger ticket service; forming a passenger ticket service by combining or reconfiguring the original secondary passenger ticket service, according to the function and the granularity of the original secondary passenger ticket service; forming a passenger ticket service functional unit according to the passenger ticket service and the passenger ticket information; forming a passenger ticket information processing service function, by combining and processing the passenger ticket service functional unit according to the service flow and the service rule for the passenger ticket; and lastly processing the passenger ticket information according to the passenger ticket information ...

Omni-directional counterbalance forklift control method and device

The invention discloses a control method for an omni-directional counterbalance forklift truck. The method specifically comprises the following steps that S1, the instantaneous center O from the current pose to the target pose at the next moment is determined; s2, calculating the linear speed of the omni-directional counterbalance forklift truck based on the instantaneous center O; and S3, the omni-directional counterweight forklift is controlled to run to the target position of the next moment at the linear speed, and the posture of the omni-directional counterweight forklift at the target position is the target posture. The omni-directional structure is adopted to replace a single steering wheel structure in a counterweight logistics forklift, synchronization of angle control and position control of the counterweight forklift is achieved, and the working efficiency and the control precision of the omni-directional counterweight forklift are improved.

Backlight module and its cable fixing structure

The invention provides a backlight module and its cable fixing structure. The cable fixing structure of the backlight module includes a main body and a plurality of buckle-up sections. The main body is disposed with a plurality of cable accommodation trough-channels, while the inner wall of each accommodation trough-channel is disposed with a stopping block. The plurality of buckle-up sections are installed onto the two laterals of the main body, while the buckle-up sections are buckled onto one back board of the backlight module, thereby to prevent the cable from falling off the cable accommodation trough-channel, and limit the cable from pulling the welding point at the end of cable due to its over-movement.

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

Monohydrate of an azaadamantane derivative

MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE Abstract 5 10 15 20 25 30 35 Two Theta (deg) The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4 thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS

The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivat ives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing s uch compounds, and intermediates obtained during such processes.

CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS

A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (HCV) inhibitors

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I).

Transmission pressurization system based on hollow motor

The invention relates to a transmission pressurization system based on a hollow motor, and belongs to the field of automobile braking. Comprising a bearing, a hollow motor, a hollow motor rotor, a lead screw, a nut, a steel ball, a push rod seat, a valve body, a push rod, a piston, an auxiliary leather cup, a main leather cup, a main cylinder body, a sliding block, a bolt and a limiting seat. The hollow motor linear thrust generator has the advantages that the structure is novel, the motor is used as a power source, the hollow motor linear thrust generator can be applied to conventional braking, brake-by-wire, active collision avoidance, self-adaptive cruise, intelligent driving and braking energy recovery systems, the ball screw is used, rotary motion of the hollow motor is changed into linear motion, thrust is generated, and the hollow motor linear thrust generator has the advantages of being high in response speed, high in robustness and the like; the piston is connected with the screw ...

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2, 3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Novel monohydrate of azaadamantane derivatives

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1, 3, 4-thiadiazol-2-yloxy)-1-azatricyclo[3. 3. 1. 13, 7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.

System and method for adjusting the distribution of an asset over a multi-tiered network

A system and method for adjusting the distribution of an asset over a multi-tiered network is provided. An asset may represent network and/or application components (e.g., data, objects, applications, program modules, etc.) that may be distributed among the various resources of the network. In an embodiment, a performance metric is received and input to a performance model. The model determines a network optimization and at least one change requirement based on the metric. A package specification is changed to reflect the requirement, which may specify that at least one asset should be packaged in at least one package. The change requirement is implemented and the package is distributed over the network.

Enterprise information system

Crystalline forms of rapamycin analogs

Automatic Electronic Information Display Device

Auxiliary adjustment device and method of wide-view-field spectral imaging system

The invention discloses an auxiliary adjustment device and method of a wide-view-field spectral imaging system. A wide view field generating part is placed in a collimation light path between a collimator and the to-be-adjusted spectral imaging system, and collimation light emitted out from the collimator is refracted by an angle slightly smaller than a semi-view-field angle of the spectral imaging system to enter the to-be-adjusted spectral imaging system, and is imaged on a detector in a light splitting mode through the to-be-adjusted spectral imaging system; a monochromatic light generating part is placed in front of the to-be-adjusted spectral imaging system, and a compound color light source passes through two narrow band light filters with different spectral signatures to enable an internal view field light bar slit of the to-be-adjusted spectral imaging system to be imaged on the detector. According to the auxiliary adjustment device and method, the problem that the detector can ...

Spray head for biogas slurry irrigation and irrigation assembly

The invention relates to the field of agricultural appliances, in particular to a spray head for biogas slurry irrigation and an irrigation assembly.The spray head for biogas slurry irrigation comprises a spray head body and a pipe connecting device, the pipe connecting device is arranged at one end of the spray head body and used for being connected with an irrigation pipeline, and a first water channel and a second water channel are arranged in the spray head body; the pressurized biogas slurry is sprayed into the air through the first water channel, the second water channel is communicated with the first water channel, and the second water channel is used for conveying clear water into the first flow channel. According to the spray head for biogas slurry irrigation, the second water channel is arranged to communicate with the first water channel, the second water channel is used for conveying clear water into the first water channel, the concentration of biogas slurry can be diluted ...

Method for determining ecological dredging range of water body pollution bottom sediment

The invention discloses a method for determining ecological dredging range of water body pollution bottom sediment, comprising steps of: performing space gridding to a water area; setting a sampling point, and obtaining bottom sediment pollution level attribute information of the sampling point; determining the water area requiring dredging after excluding the water area without dredging; processing space interpolation to the bottom sediment attribute information of the water area to cover an unsampled water area with the attribute information, and obtaining the mean value of the single attribute information of the space interpolation in a grid cell, and grading the attribute, and rounding the attribute mean value of the grid cell hierarchically; performing dimensionless standardization treatment of 0-1 numerical values to the hierarchically rounded attribute information, and obtaining the evaluation coefficient of each attribute of the grid cell, summing the evaluation coefficients of ...

System for achieving transient signal capture and spectral analysis

The invention relates to a system for achieving transient signal capture and spectral analysis. The system comprises a superheterodyne receiver and a digital intermediate frequency capture and analysis module. The digital intermediate frequency capture and analysis module comprises an analog-digital conversion unit, an IQ modulation unit, a rapid Fourier transform unit and a mapping and recording unit. The mapping and recording unit is used for calculating the signal amplitude of each frequency component output by the rapid Fourier transform unit, conducting probability mapping on the signal amplitudes and recording the appearing frequency of frequency points. According to the system for achieving transient signal capture and spectral analysis, by the adoption of the structure, the information of the frequency, amplitude and occurrence probability and time of signals can be analyzed and recorded at the same time, the method for comprehensively analyzing suddenly-burst signals is provided ...

Catalyst for carbonylsynthesizing diethyl carbonate byethanol gas-phase oxidation and preparation method thereof

The invention discloses a catalyst for synthesizing diethyl carbonate with ethanol gas phase carbon oxide and a preparation method. The active components of the catalyst are CuCl, CuCl2, Cu (NO3)2 or Cu (Ac) 2, and a carrier is H Beta, HZSM-5, or HY molecular sieve. The preparation method is: the copper salt is added into HCI solution, and the molecular sieve carrier is soaked in the solution, and NH3.H2O is added drop by drop for precipitation. The obtained solid catalyst raises temperature under the protection of N2 and is heated with constant temperature, and is cooled naturally to the room temperature, so that the catalyst is obtained. The invention has the advantages that the catalyst made for the reaction of synthesizing diethyl carbonate with ethanol gas phase carbon oxide has the advantages of the high selectivity of the target product diethyl carbonate, the cheap and easy access to the catalyst and the stability of the catalytic activity.

Low-altitude control and anti-unmanned aerial vehicle integrated command vehicle system and control method

The invention provides a low-altitude control and anti-unmanned aerial vehicle integrated command vehicle system and a control method, and belongs to the field of vehicle-mounted unmanned aerial vehicle prevention and control, and the method comprises the steps: making a prevention and control plan, and setting a protection region, a denial region and an early warning region; drawing a flight airspace of the vehicle-mounted unmanned aerial vehicle, planning a flight route, making a flight plan, receiving a flight plan reply, controlling the vehicle-mounted unmanned aerial vehicle to take off and execute a task, and adding the task into a white list; identifying the unmanned aerial vehicle after detecting that the unmanned aerial vehicle enters the early warning area, generating target early warning information and adding the target early warning information into a blacklist; when the unmanned aerial vehicle in the blacklist enters the denial area, judging whether the type of the unmanned ...

Particle characterization apparatus and method

An apparatus is provided for determining particle characteristics, in which a flow path is generated containing particles to be analyzed. A light detection system detecting light received from a measurement zone which has been scattered by the particles. A time duration for which a particle remains in the measurement zone is measured to determine an effective aerodynamic particle diameter and a peak detected received light intensity is measured to determine an effective optical particle diameter. A further particle parameter is also obtained relating to the shape and/or density of the particle. This approach enables more information than only a particle size to be obtained using a single-stage optical analysis system. The additional information may be used to characterize the particles more accurately.

System and method for transactional deployment of J2EE web components, enterprise java bean components, and application data over multi-tiered computer networks

Provided is a computer system and method for transactional deployment of component(s) over a multi-tier network with J2EE application server program(s) stored on a memory(ies) of the system and which are executed by a central processing unit(s) (CPUs). A J2EE application(s) can be executed by the J2EE application servers, and a J2EE application container(s) are contained within each J2EE application server. Each J2EE application container contains a J2EE application container component(s) and a Java EJB container(s) or Java web containers are contained within each J2EE application container. A J2EE component(s) are delivered to the J2EE application server over one or more tiers of the network. There are one or more logical connections to one or more databases located on the network. This defines a sphere of control managing transactional deployment of the delivered J2EE component(s) and an update of the database to keep the data consistent with the J2EE application. 1. A computer system in a network environment for transactional deployment of at least one component , the computer system having access to at least one storage device containing a database , the computer system comprising:a processor;at least one memory device containing at least one J2EE application server program adapted to be executed by the processor, the at least one J2EE application server program containing at least one J2EE application, the at least one J2EE application having at least one J2EE application container, the at least one J2EE application container having at least one J2EE application container component, the at least one J2EE application server program adapted to receive at least one J2EE component delivered from the network environment over at least one tier of the network; anda means for providing a logical connection to the database;wherein the at least one J2EE application server program, the at least one J2EE application, the at least one J2EE application container, the at ...

ANTI-INFECTIVE AGENTS AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. (E)-N-(4-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide crystalline form selected from the group consisting of:crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide disodium salt nonahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide disodium salt tetrahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide dipotassium salt tetrahydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monopotassium salt trihydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monopotassium salt dihydrate;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide 1/7 potassium salt;crystalline (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide monodiethylamine salt tetrahydrate;crystalline pattern A (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide;crystalline pattern B (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide;crystalline pattern C (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2- ...

ANTI-INFECTIVE AGENTS AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. A crystalline form of N-(6-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide and salts thereof.2. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of a solvate claim 1 , a hydrate and a solvent-free crystalline form.3. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of:crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide acetonitrile solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide ethyl acetate solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide 2-propanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide methanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide 1-propanol solvate;crystalline solvent free N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl) ...

System and Method for Distributing Assets to Multi-Tiered Network Nodes

Provided are methods and systems for distributing an asset to a multi-tiered network node. A pending notice is received from a distribution server. If the notice indicates that at least one asset is pending, i.e., awaiting deployment, an asset descriptor manifest is received from the distribution server. The asset descriptor manifest, which is stored in a memory on a node, identifies at least one asset to be deployed to the node and includes an offset associated with the asset identifier. A fragment, associated with the asset, is received and stored in the memory. The offset associated with the asset is marked with the end of the fragment and a second fragment, beginning at the offset, is received. Additional fragments are received, and the offset updated, until the entire asset is deployed to the node. Alternately, the entire asset or multiple assets are received in the first fragment. 1. A method for distributing assets to multi-tiered network nodes , comprising:sending an asset deployment query from a target node to a content distribution server, the query including a target identifier;searching an asset deployment queue for the target identifier;indicating, to the target node, whether the target identifier was found in the deployment queue;sending a request for an asset descriptor manifest from the target node to the content distribution server;identifying at least one asset that needs to be distributed to the target node;creating an asset manifest entry associated with each asset that needs to be distributed to the target node;assembling the asset descriptor manifest from at least one asset manifest entry;sending the asset descriptor manifest from the content distribution server to the target node;determining at least one asset associated with at least one asset manifest entry;sending a request for the asset from the target node to the content distribution server;creating a data structure associated with the asset; andsending the data structure from the content ...

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. 2. The compound according to claim 1 , wherein{'sub': '1', 'A is Ar.'}4. The compound according to claim 3 , wherein{'sub': '1', 'Lis —O—.'}5. The compound according to claim 3 , wherein{'sub': 1', 'a, 'Lis —NR—.'}6. The compound according to claim 1 , wherein{'sub': 2', '2', '3, 'A is —Ar-L-Ar.'}9. The compound according to claim 6 , wherein{'sub': 1', 'a, 'Lis —NR—; and'}{'sub': '2', 'Lis a bond.'}10. The compound according to claim 6 , wherein{'sub': '1', 'Lis —O—; and'}{'sub': '2', 'Lis a bond.'}11. The compound according to claim 1 , wherein{'sub': 4', '3', '5, 'A is —Ar-L-Ar.'}13. A compound of claim 1 , wherein the compound is{'sup': '3,7', '(4s)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-bromopyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[5-(1H-indol-5-yl)pyridin-2-yloxy]-1- ...

FILTER ELEMENT AND GAS PURIFICATION DEVICE COMRPISING A FILTER ELEMENT

A filter element () for use in a gas purification device () is disclosed. It comprises a substrate () and a filter layer () covering an exterior surface of the substrate (). The substrate () comprises material for containing chemicals () effective to remove gas pollutants from a gas. The material of the filter layer () is hydrophilic to adsorb liquid solution adsorbents effective in removing gas pollutants from a gas, and the exterior surface of the substrate () covered by the filter layer () is hydrophobic. 1. Filter element for use in a gas purification device , comprising a substrate and a filter layer covering an exterior surface of the substrate , wherein the substrate comprises material for containing chemicals effective to remove gas pollutants from a gas , wherein the material of the filter layer is hydrophilic to adsorb liquid solution adsorbents effective in removing gas pollutants from a gas , and wherein the exterior surface of the substrate covered by the filter layer is hydrophobic.2. Filter element according to claim 1 , wherein the substrate comprises a plurality of channels claim 1 , and wherein the filter layer covers at least a portion of the exterior surface of the substrate in the channels.3. Filter element according to claim 2 , wherein the substrate has a honeycomb appearance by virtue of at least a portion of the channels having a hexagonal outline.4. Filter element according to claim 2 , wherein the channels are non-straight channels claim 2 , i.e. channels different from straight channels extending in a single longitudinal direction.5. Filter element according to claim 1 , wherein the substrate comprises a hydrophilic material such that only its exterior surface is hydrophobic.6. Filter element according to claim 1 , wherein the substrate is entirely made of hydrophobic material.7. Device for purifying a gas such as air claim 1 , comprising a filter element according to claim 1 , and means for realizing a flow of the gas along the filter ...

A METHOD FOR TREATING A SURFACE AND AN ARTICLE COMPRISING A LAYER OF MICROBIAL STRUCTURES

The present invention provides a method of treating a surface of a substrate, the method comprising: a) growing a microbe on the surface of the substrate to be treated to form a layer of microbial structures, wherein the microbe is selected from fungi, algae, lichens and any combination thereof; and b) coating the microbial structures to form a first coating thereon, wherein the first coating has a thickness of no more than 1 μm. The present invention also provides an article comprising a layer of microbial structures, optionally made by using the method of the present invention. 1. A method of treating a surface of a substrate , the method comprising:a) growing a microbe on the surface of the substrate to be treated to form a layer of microbial structures, wherein the microbe is selected from fungi, bacteria, algae, lichens and any combination thereof; andb) coating the microbial structures to form a first coating thereon, wherein the first coating has a thickness of no more than 1 μm.2. A method according to claim 1 , wherein the microbe is selected from fungi or bacteria comprising hyphae with a diameter of between 0.3 μm and 100 μm.3. A method according to claim 2 , wherein the fungi or bacteria are selected from Molds claim 2 , Actinomycetes and any combination thereof.4Rhizopus, Mucor, Neurospora, Aspergillus, Penicillium, Streptomyces, Nocardia, Frankia, Actinoplanes, thermomonospora. A method according to claim 3 , wherein the fungi or bacteria are selected from and any combination thereof.5StreptomycesStreptomyces albus, Streptomyces griseus, Streptomyces venezuelae, Streptomyces aureofaciens. A method according to claim 4 , wherein the is selected from and any combination thereof.6. A method according to claim 1 , wherein the first coating is formed on the microbial structures by one or more methods selected from vapor deposition claim 1 , self-propagation high-temperature synthesis claim 1 , thermochemical synthesis claim 1 , thermal spraying claim 1 , ...

AUTOMATED BATCH APPLICATION PROGRAMMING INTERFACES

In one general aspect, a method for rendering a web page can include receiving, from an interactive web application executing on a computing device, a plurality of application programming interface (API) calls for information and data for including in the rendering of the web page by the interactive web application, determining, for each of the plurality of API calls, whether an API call satisfies at least one criterion, storing, in a memory included on a computing device, an API call for inclusion in a batch of API calls if the API call satisfies the at least one criterion, and sending, in a single API call, the batch of API calls stored in the memory, the sending based on an occurrence of an event in the computing device. 1. A method for rendering a web page , the comprising:receiving, from an interactive web application executing on a computing device, a plurality of application programming interface (API) calls for information and data for including in the rendering of the web page by the interactive web application;determining, for each of the plurality of API calls, whether an API call satisfies at least one criterion;storing, in a memory included on a computing device, an API call for inclusion in a batch of API calls if the API call satisfies the at least one criterion; andsending, in a single API call, the batch of API calls stored in the memory, the sending based on an occurrence of an event in the computing device.2. The method of claim 1 , further comprising:receiving a skeleton of the web page before receiving the API call.3. The method of claim 1 ,wherein determining, for each of the plurality of API calls, whether an API call satisfies at least one criterion includes determining that the API call occurs between a first tick and a second tick of an event loop executing on the computing device.4. The method of claim 3 , wherein the event is the second tick of the event loop.5. The method of claim 1 , wherein the event is the determining that a number of ...

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease. This application is a continuation of International Patent Application No. PCT/US2019/038459, filed on Jun. 21, 2019, which claims the benefit of, and priority to, U.S. Provisional Application No. 62/688,226, filed on Jun. 21, 2018, the contents of each of which are incorporated herein by reference in their entirety.Cancer immunotherapy regimens targeting immune evasion mechanisms including checkpoint blockade (e.g. PD-1/PD-L1 and CTLA-4 blocking antibodies) have been shown to be effective in treating in a variety of cancers, dramatically improving outcomes in some populations refractory to conventional therapies. However, incomplete clinical responses and the development of intrinsic or acquired resistance will continue to limit the patient populations who could benefit from checkpoint blockade.Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is an intracellular member of the class 1 subfamily of phospho-tyrosine specific phosphatases that control multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates. PTPN2 is ubiquitously expressed, but expression is highest in hematopoietic and placental cells (Mosinger, B. Jr. et al., 89:499-503; 1992). In humans, PTPN2 expression is controlled post-transcriptionally by the existence of two splice variants: a 45 kDa form that contains a nuclear localization signal at the C-terminus upstream of the splice junction, and a 48 kDa canonical form which has a C-terminal ER retention motif (Tillmann U. et al., 14:3030-3040; 1994). The 45 kDa ...

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; andthus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether CFOCH.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in ...

OPTICAL SIGNAL-TO-NOISE RATIO MEASURING METHOD

An OSNR measuring method, comprising: measuring a spectrum to be measured of an optical signal at a point to be measured of an optical transmission line, and acquiring the comparative spectrum of the optical signal within a channel wavelength range and at an SNR different from the SNR of the point to be measured; respectively integrating, within the channel wavelength range of the optical signal, the spectrum to be measured and the comparative spectrum to obtain total power Pspectrum to be measured and Pcomparative spectrum, and acquiring a noise factor F and a signal scale factor A; calculating, according to the total power, the noise factor and the signal scale factor, the noise power Pspectrum to be measured within the channel wavelength range of the optical signal, so as to obtain an OSNR of the point to be measured. 1. An optical signal-to-noise ration measuring method , comprising the following steps:measuring spectrum to be measured of measured optical signal at spot to be measured on optical transmission line, wherein the spectrum to be measured includes spectrum power density distribution of the measured optical signal in the channel wavelength range B;obtaining spectrum to be compared, which includes spectrum power density distribution of the measured optical signal or signal with same spectrum feature as that of the measured optical signal, under SNR different from that of the spot to be measured in the channel wavelength range B;in the channel wavelength range B, integrating the spectrum to be measured and the spectrum to be compared, respectively, to obtain total powers of the spectrum to be measured and the spectrum to be compared; andaccording to integral power relationship and OSNR relationship between optical signal parts of the spectrum to be measured and the spectrum to be compared, using the obtained total powers of the spectrum to be measured and the spectrum to be compared to estimate the OSNR at the spot to be measured.9. The in-band OSNR ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 1. A compound 4-(4-{[2-(4-chlorophenyl)-4 ,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2 ,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a crystalline form , wherein the crystalline form is Compound 1 free base hydrate , characterized by a powder X-ray diffraction pattern having five or more peaks selected from those at 3.3 , 6.4 , 7.1 , 7.3 , 10.1 , 11.4 , 13.2 , 14.4 , 14.6 , 15.1 , 15.8 , 16.2 , 17.2 , 17.6 , 18.0 , 18.6 , 19.0 , 19.5 , 19.8 , 20.2 , 20.7 , 21.0 , 22.5 , 23.0 , 26.0 , 28.9 , and 29.2 degrees 2θ (pattern D) , each peak being ±0.2 degrees 2θ , when measured at about 25° C. with Cu Kradiation at 1.54178 Å.2. A pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.3. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving the compound of in a pharmaceutically acceptable solvent or mixture of solvents.4. A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein claim 1 , comprising administering to a subject having the disease a therapeutically effective amount of (a) the compound of or (b) a pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.5. The method of claim 4 , wherein the compound or pharmaceutical composition is administered by an oral claim 4 , parenteral claim 4 , sublingual claim 4 , buccal claim ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 1. A compound 4-(4-{[2-(4-chlorophenyl)-4 ,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2 ,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a crystalline form , wherein the crystalline form is Compound 1 free base hydrate , characterized by a powder X-ray diffraction pattern having five or more peaks selected from those at 5.8 , 7.6 , 7.9 , 10.7 , 11.7 , 14.0 , 15.3 , 15.8 , 17.4 , 18.3 , 19.9 , 20.4 , 20.7 , 22.5 , 24.9 , 25.8 , and 26.7 degrees 2θ (pattern C) , each peak being ±0.2 degrees 2θ , when measured at about 25° C. with Cu Kradiation at 1.54178 Å.2. A pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.3. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving the compound of in a pharmaceutically acceptable solvent or mixture of solvents.4. A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein claim 1 , comprising administering to a subject having the disease a therapeutically effective amount of (a) the compound of or (b) a pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.5. The method of claim 4 , wherein the compound or pharmaceutical composition is administered by an oral claim 4 , parenteral claim 4 , sublingual claim 4 , buccal claim 4 , intranasal claim 4 , pulmonary claim 4 , topical claim 4 , ...

AIR PURIFIER AND AIR PURIFICATION METHOD

An air purifier comprise a gas filter between an upstream air flow and a downstream air flow and a concentration sensor comprising a first electrode and a second electrode, the first electrode being exposed to the upstream air flow and the second electrode exposed to the downstream air flow, the concentration sensor providing an output signal based on the difference in concentrations of a target gas at the first and second electrodes. The output signal is processed to determine information relating to the con- dition of the gas filter. 1. An air purifier , comprising:a gas filter located between an upstream air flow and a downstream air flow;a concentration sensor comprising a first electrode and a second electrode, the first electrode being exposed to the upstream air flow and the second electrode exposed to the downstream air flow, wherein the concentration sensor comprises an electrolyte located between the first and second electrodes, and wherein the concentration sensor is configured for providing an output signal based on the difference in concentrations of a target gas at the first and second electrodes; anda processor configured for processing the output signal to determine information relating to the condition of the gas filter.2. An air purifier as claimed in claim 1 , further comprising a calibration module configured for calibrating the concentration sensor based on an initial target gas concentration level.3. An air purifier as claimed in claim 2 , wherein the calibration module comprises:an additional sensor exposed to the upstream air flow; ora reference electrode exposed to a confined gas volume; ora user interface for receiving the initial target gas concentration level from a user; ora communications module for receiving the initial target gas concentration level from an external data source.4. An air purifier as claimed in claim 1 , further comprising a calibration modulecomprising a reference electrode exposed to a confined gas volume, and ...

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition. 1. A method of forming a powdered hemostatic composition , comprising the steps of:a) forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent;b) spraying the suspension through a nozzle onto a substrate,c) allowing the non-aqueous solvent to evaporate;d) separating the composition from the substrate and sieving the composition; and thus forming the powdered hemostatic composition.2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether C4F9OCH3.3. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said suspension comprises a fibrin sealant powder which comprises about 90% of fibrinogen claim 1 , about 8% of thrombin claim 1 , and about 2.5% calcium chloride by weight.7. The method of claim 6 , wherein said powdered hemostatic composition has a ratio of fibrin sealant powder to ORC from about 1:1 to about 10:1 by weight.8. The method of claim 1 , wherein said powdered hemostatic composition comprises powder having particle size predominantly in the range from about 250 to about 850 microns.9. The method of claim 8 , wherein said powdered hemostatic composition comprises powder having particle size ...

CONTROL DEVICE, SWITCH DEVICE AND METHODS

A control device for a software programmable network including one or more nodes and supporting traffic of guaranteed quality of service, QoS, and best-effort, BE, traffic with a predetermined resource distribution between guaranteed QoS and BE service classes, comprises: a processing circuitry configured to determine a new resource distribution between guaranteed QoS and BE service classes different from the predetermined resource distribution according to a demand for QoS service, to calculate, for each node, a new configuration indicating the new resource distribution, and to calculate, for each entry node to the network among the one or more nodes, a label distribution sequence indicating one or more label distributions with associated activation timing information so as to reduce jitter or packet loss; and a transceiver configured to transmit the new configurations to respective nodes, and to transmit the label distribution sequences to respective entry nodes. 1. A control device comprising:processing circuitry configured to:determine a new resource distribution between guaranteed QoS and BE service classes different from predetermined resource distribution according to a demand for QoS service;calculate, for each node of one or more nodes in a network, a new configuration indicating the new resource distribution; andobtain, for each entry node to the network among the one or more nodes, a label distribution sequence indicating one or more label distributions with associated activation timing information; anda transceiver configured to:transmit the new configurations to respective nodes; andtransmit the label distribution sequences to respective entry nodes.2. The control device according to claim 1 , wherein claim 1 ,the new configurations indicate a repartition of queues configured for guaranteed QoS and BE service classes.3. The control device according to claim 1 , wherein claim 1 ,the new configurations indicate a repartition of bandwidth for guaranteed ...

SECURE COMPUTER-IMPLEMENTED EXECUTION AND EVALUATION OF PROGRAMMING ASSIGNMENTS FOR ON DEMAND COURSES

In one general aspect, a computer-implemented method can include receiving, by a computer system, code for a custom grader application, creating, by the computer system, a base custom grader container including the code for the custom grader application, associating the base custom grader container with an online course included in a repository included in the computer system, evaluating, by the computer system, the base custom grader container by executing the custom grader application in the base custom grader container, determining that the custom grader application violates a predetermined criterion, modifying the base custom grader container to prevent the executing of the custom grader application from violating the predetermined criterion, and storing, in the repository and in association with the online course, the modified base custom grader container including the custom grader application as a custom grader container image. 1. A computer-implemented method comprising:receiving, by a computer system, code for a custom grader application;creating, by the computer system, a base custom grader container including the code for the custom grader application;associating the base custom grader container with an online course included in a repository included in the computer system;evaluating, by the computer system, the base custom grader container by executing the custom grader application in the base custom grader container;determining that the custom grader application violates a predetermined criterion;modifying the base custom grader container to prevent the executing of the custom grader application from violating the predetermined criterion; andstoring, in the repository and in association with the online course, the modified base custom grader container including the custom grader application as a custom grader container image.2. The method of claim 1 , further comprising:receiving, by the computer system, a programming assignment for the online course ...

PARTICLE SENSOR AND PARTICLE SENSING METHOD

A particle sensing system is for sensing particles entrained in a fluid. The system comprises a flow channel having a longitudinal direction along which the fluid is to be passed, a heating arrangement for heating the fluid and thereby applying a positive thermophoretic force on the fluid in a direction perpendicular to the longitudinal direction of the flow channel and a first sensor for sensing the particles in the fluid after heating by the heating arrangement. The thermophoretic force increases the concentration of the particles at the first sensor. 1. A particle sensing system for sensing particles entrained in a fluid , comprising:a detection volume located within a flow channel through which the fluid is to be passed in a longitudinal direction;a heating arrangement for generating a thermal gradient perpendicular to the fluid flow direction and thereby applying a positive thermophoretic force to particles entrained in the fluid; anda sensor for sensing the particles in the fluid at the detection volume, wherein the thermophoretic force is used to constrict the space occupied by the particles within the flow and thereby concentrate the particles within the detection volume,wherein the heating arrangement is adjustable to provide different levels of thermophoretic force on the fluid, andwherein the system further comprises a controller which is adapted to:obtain an initial particle concentration measurement with no heating; andcontrol the heating arrangement in dependence on the initial particle concentration measurement.2. A system as claimed in claim 1 , wherein the heating arrangement comprises a plurality of independently controllable heating elements.3. A system as claimed in claim 1 , wherein the detection volume has a smaller cross sectional area than that of the flow channel.4. A system as claimed in claim 1 , wherein the heating arrangement comprises a coil or set of coils surrounding the flow channel.5. A system as claimed in claim 1 , wherein the ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 1. A compound having the systematic name 4-(4-{[2-(4-chlorophenyl)-4 ,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2 ,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a salt or crystalline form.2. The compound of claim 1 , wherein the crystalline form is Compound 1 free base anhydrate claim 1 , characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 6.3 claim 1 , 7.1 claim 1 , 9.0 claim 1 , 9.5 claim 1 , 12.5 claim 1 , 14.5 claim 1 , 14.7 claim 1 , 15.9 claim 1 , 16.9 claim 1 , and 18.9 degrees 2θ (pattern A) claim 1 , each peak being ±0.2 degrees 2θ claim 1 , when measured at about 25° C. with Cu K radiation at 1.54178 Å.3. The compound of claim 1 , wherein the crystalline form is Compound 1 free base anhydrate claim 1 , characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 5.8 claim 1 , 7.7 claim 1 , 8.3 claim 1 , 9.9 claim 1 , 13.0 claim 1 , 13.3 claim 1 , 14.2 claim 1 , 15.3 claim 1 , 16.6 claim 1 , 17.9 claim 1 , 18.3 claim 1 , 19.8 claim 1 , 20.7 claim 1 , 21.2 claim 1 , 21.9 claim 1 , 22.5 claim 1 , 23.6 claim 1 , and 24.1 degrees 2θ (pattern B) claim 1 , each peak being ±0.2 degrees 2θ claim 1 , when measured at about 25° C. with Cu K radiation at 1.54178 Å.4. The compound of claim 1 , wherein the crystalline form is Compound 1 free base hydrate claim 1 , characterized by a powder X-ray diffraction pattern having at least one peak selected from ...

INFRARED AUTOMOBILE CHARGING SYSTEM

An infrared automobile charging system includes: a photovoltaic battery panel installed at a bottom of a vehicle; a camera module; a first actuating device connected with the camera module; an infrared light source; a second actuating device connected with the infrared light source; and a controller being connected with the camera module, the first actuating device, the infrared light source and the second actuating device. The controller is configured to control the first actuating device to rotate, and through the first actuating device control the camera module to capture a preset pattern disposed at the bottom of the vehicle. After the camera module has captured the preset pattern disposed at the bottom of the vehicle, the controller is configured to control the second actuating device to rotate accordingly so that the infrared light source projects infrared light to the photovoltaic battery panel and thereby charge the photovoltaic battery panel. 1. An infrared automobile charging system comprising:a photovoltaic battery panel installed at a bottom of a vehicle;a camera module;a first actuating device connected with the camera module;an infrared light source;a second actuating device connected with the infrared light source; anda controller being connected with the camera module, the first actuating device, the infrared light source and the second actuating device;the controller being configured to control the first actuating device to rotate, and through the first actuating device control the camera module to capture a preset pattern disposed at the bottom of the vehicle;after the camera module has captured the preset pattern disposed at the bottom of the vehicle, the controller being configured to control the second actuating device to rotate accordingly so that the infrared light source projects infrared light to the photovoltaic battery panel and thereby charge the photovoltaic battery panel; wherein:the camera module, the first actuating device, the ...

Distributed Cloud Services System and Uses Thereof

Provided herein is a non-transitory computer readable medium comprising software configured to enable instructions to create of a multidimensional value model for an event, such as, a travel event. When executed information related to events from all sources is stored and categorized according to the source, value dimension and value description of the event are established and used to create an initial multidimensional value model. If the event is a travel event, the initial model is updated according to user-selected travel events and a recommendation for travel made to the user based on the updated model. Also provided is a distributed cloud computer system that integrates cloud computing with a 1. A non-transitory computer readable medium comprising software for creating a multidimensional value model for an event , which when executed using at least one computer having at least a memory , a processor and a network connection , is configured to enable instructions to:a) receive information related to one or more events of interest from all available sources;b) store and categorize the event and information related thereto in a raw information library;c) establish a value dimension and value description of the event; andd) create an initial multidimensional value model for the event from the value dimension and the value description.2. The non-transitory computer readable medium of claim 1 , further configured to enable instructions to update the multidimensional value model via iteration of steps a to d.3. The non-transitory computer readable medium of claim 1 , wherein the event is a travel event claim 1 , said computer readable medium further configured to enable instructions to claim 1 , in real time:e) receive events selected by a user;f) modify the value dimension and value description of the user-selected event in the multidimensional value model; andg) present the modified multidimensional value model to the user as a best travel recommendation based on ...

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. 2. The compound according to claim 1 , wherein{'sub': '1', 'A is Ar.'}4. The compound according to claim 3 , wherein{'sub': '1', 'Lis —O—.'}5. The compound according to claim 3 , wherein{'sub': 1', 'a, 'Lis —NR—.'}6. The compound according to claim 1 , wherein{'sub': 2', '2', '3, 'A is —Ar-L-Ar.'}9. The compound according to claim 6 , wherein{'sub': 1', 'a, 'Lis —NR—; and'}{'sub': '2', 'Lis a bond.'}10. The compound according to claim 6 , wherein{'sub': '1', 'Lis —O—; and'}{'sub': '2', 'Lis a bond.'}11. The compound according to claim 1 , wherein{'sub': 4', '3', '5, 'A is —Ar-L-Ar.'}13. A compound of claim 1 , wherein the compound is{'sup': '3,7', '(4s)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-chloropyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(6-phenylpyridazin-3-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-[6-(1-benzothien-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-bromopyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4r)-4-(5-phenylpyridin-2-yloxy)-1-azatricyclo[3.3.1.1]decane;'}{'sup': '3,7', '(4s)-4-[5-(1H-indol-5-yl)pyridin-2-yloxy]-1- ...

Particle sensor and method

A particle sensor is provided for sensing the number or mass concentration of particles within a particular particle size range, the particles having a particle size distribution. The sensor comprises a light source (14) for providing light which is scattered by the particles to generate scattered light; a light detector (16, 18) for detecting the scattered light to provide a light detector signal; and a controller (24) for analyzing the light detector signal to determine information relating to the particle size distribution. Based on that information relating to the particle size distribution, the controller selects a mode of operation of the particle sensor to sense the particles only within the particular size range.

SYSTEM AND METHOD FOR ALERTING A CAREGIVER BASED ON THE STATE OF A PERSON IN NEED

The invention provides a system for alerting a second subject (e.g. a parent) based on a wellbeing state of a first subject (e.g. a child) when the first subject is sleeping in the same room as the second subject. An arrangement of sensors is used for sensing data from the first subject and a processor is configured to determine the presence of the first subject from the sensing data. Based on the first subject being present, the processor is further configured to determine the state of the first subject based on the sensing data from the arrangement of sensors and then determine whether to alert the second subject based on the state of the first subject. An alarm is provided for alerting the second subject. 1. A system for alerting a second subject based on a wellbeing state of a first subject when the first subject is sleeping in the same room as the second subject , comprising:an arrangement of sensors for sensing data from the first subject and for sensing data for the second subject;a processor configured to:determine the presence of the first subject in the room from the sensing data; and determine a wellbeing state of the first subject based on the sensing data from the arrangement of sensors;', 'determine a wellbeing state of the second subject; and, 'based on the first subject being present 'an alarm for alerting the second subject.', 'determine whether to alert the second subject based on the wellbeing state of the first subject and the wellbeing state of the second subject; and'}2. A system as claimed in further for alerting a third subject when the third subject is sleeping in the same room as the first and second subject claim 1 , comprising a second alarm for alerting a third subject claim 1 , wherein the arrangement of sensors is further configured to sense data for the third subject and the processor is further configured to determine a wellbeing state of the third subject claim 1 , wherein the processor is configured to determine whether to alert ...

LITHIUM COBALT METAL OXIDE POWDER, METHOD FOR MAKING THE SAME, AND METHOD FOR DETERMINING CONTENT OF COBALT (II,III) OXIDE

A lithium cobalt metal oxide powder is disclosed in the present disclosure. The lithium cobalt metal oxide powder has a coating structure. The lithium cobalt metal oxide powder includes a lithium cobalt metal oxide matrix. The lithium cobalt metal oxide powder further includes a CoOcoating layer. A general formula of the lithium cobalt metal oxide powder is LiCoMNO.rCoO, wherein 0.002 Подробнее

BORATE COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USES THEREOF

A borate compound serving as a proteasome inhibitor, a preparation method for the borate compound and uses thereof. 2. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the circular portion jointly formed by the Xand the Xby removing hydrogen atoms of two functional groups of the boric acid esterifying agent is a 5 to 12 membered ring.3. The compound or the pharmaceutically acceptable salt thereof according to claim 2 , wherein:the boric acid esterifying agent is selected from the group consisting of salicylic acid, mandelic acid, lactic acid and iminodiacetic acid substituted by a substituent or unsubstituted; the substituent is selected from the group consisting of halogens, amino, C1-6 alkyls, C3-C8 cycloalkyls, C2-C6 carboxyalkyls and C1-6 hydroxyalkyls and a mixture thereof;optionally, the phenyl in the salicylic acid or the mandelic acid substituted by a substituent or unsubstituted as the boric acid esterifying agent is hydrogenated or partially hydrogenated.10. The preparation method according to claim 8 , whereinthe condensation reactions in the steps a) and b) are performed in presence of organic alkali.11. A use of the compound according to in preparing medicaments for treating cancers.12. The compound or the pharmaceutically acceptable salt thereof according to claim 3 , wherein:the mandelic acid is R-mandelic acid or S-mandelic acid, and the lactic acid is L-lactic acid.13. The compound or the pharmaceutically acceptable salt thereof according to claim 4 , the boric acid esterifying agent is the salicylic acid or the R-mandelic acid.14. The preparation method according to claim 9 , wherein:an alkali used in the saponification reaction in the step a) is NaOH;a condensing agent used in the condensation reaction in the step b) is EDCl/HOBT;a reaction solvent used in the condensation reaction in the step b) is dichloromethane;in the step c), the inorganic acid is the hydrochloric acid; andin the step d), a reaction ...

SECURE COMPUTER-IMPLEMENTED EXECUTION AND EVALUATION OF PROGRAMMING ASSIGNMENTS FOR ON DEMAND COURSES

A computer system includes a course repository and a server. The course repository includes a video of an online course, an instructor provided output for a programming assignment associated with the online course, and a submission script for generating student provided output for the programming assignment. The server includes a submission module that receives and verifies the student provided output for the programming assignment. The server further includes one or more built-in grader applications that compare the student provided output with the instructor provided output to determine a grade for the programming assignment. 1. A computer system comprising: a video of the online course;', 'instructor provided output for a programming assignment associated with the online course; and', 'a submission script for generating student provided output for the programming assignment; and, 'a course repository including [ receive the student provided output for the programming assignment generated by the submission script; and', 'verify the student provided output for the programming assignment; and, 'a submission module configured to, compare the student provided output for the programming assignment to the instructor provided output for the programming assignment; and', 'generate a grade for the programming assignment based on the comparison., 'one or more built-in grader applications configured to], 'a server including2. The system of claim 1 , wherein the server is configured to provide the submission script to a computing device for execution in a local application included in the computing device claim 1 , and wherein the received student provided output for the programming assignment generated by the submission script is received from the computing device.3. The system of claim 1 , wherein verifying the student provided output for the programming assignment includes determining that contents of the student provided output for the programming assignment are in a ...

AIR PURIFIER INCLUDING AIR FILTER LIFE-TIME INDICATOR AND METHOD FOR DETERMINING THE LIFE-TIME OF AN AIR FILTER

Presented is an air purifier (), comprising: an air inlet (); an air outlet (); a first sensor () configured for determining a water molecule adsorption level of a filter () for removing gas pollutants or particles from air propagating from the air inlet () to the air outlet (); a processor () configured to determine a life-time of the filter () based on a water molecule adsorption level of the filter () measured by the first sensor (). Further, a method () for determining a life-time of a filter () for removing gas pollutants or particles from air is presented. 1. An air purifier , comprising:an air inlet;an air outlet;a filter for removing gas pollutants or particles from air propagating from the air inlet to the air outlet;a first sensor for determining a water molecule adsorption level of the filter;a processor configured to determine a life-time of the filter based on a water molecule adsorption level of the filter measured by the first sensor.2. The air purifier according to claim 1 , wherein the first sensor is a relative humidity sensor positioned for measuring a relative humidity of air filtered by the filter; and a processor configured to determine the life-time of the filter based on the relative humidity value measured by the first sensor.3. The air purifier according to claim 2 , further comprising a memory and wherein the processor is configured to store a plurality of relative humidity values measured by the first sensor in the memory and relate changing characteristics of the plurality of relative humidity values to the life-time of the filter.4. The air purifier claim 2 , according to claim 2 , further comprising a memory and wherein the processor is configured to store a plurality of relative humidity datasets measured by the first sensor in the memory claim 2 , each dataset comprising different relative humidity values of filtered air for a relative humidity value of ambient air claim 2 , and wherein determining the life-time of the filter is ...

TWO-DIMENSIONAL CODE IDENTIFICATION AND POSITIONING

The present specification provides a two-dimensional code identification method and device, and a two-dimensional code positioning and identification model establishment method and device. The two-dimensional code identification method includes: obtaining a to-be-identified two-dimensional code, and performing global feature positioning detection on the to-be-identified two-dimensional code by using a pre-established two-dimensional code positioning and identification model; performing focus adjustment, based on a predetermined image resolution, on the to-be-identified two-dimensional code on which positioning detection is performed; and decoding the to-be-identified two-dimensional code on which focus adjustment is performed. The present specification can improve the identification accuracy of two-dimensional codes shot in complex scenarios. 3128. The computer-implemented method of claim , wherein obtaining the two or more images that represent the one or more reference two-dimensional codes using the determined sampling mode comprises:obtaining the first image of the two or more images at a first angle; andobtaining the second image of the two or more images at a second angle.3228. The computer-implemented method of claim , wherein obtaining the two or more images that represent the one or more reference two-dimensional codes using the determined sampling mode comprises:obtaining the first image of the two or more images corresponding to a first environment condition; andobtaining the second image of the two or more images corresponding to a second environment condition.3328. The computer-implemented method of claim , wherein the global features comprise four corner points corresponding to an upper left corner , a lower left corner , an upper right corner , and a lower right corner.3428. The computer-implemented method of claim , wherein the two-dimensional code positioning and identification model comprises a machine learning network , and wherein the machine ...

DOUGH-MIXING CONTROL METHOD AND DEVICE CAPABLE OF DETERMINING DOUGH GLUTEN DEVELOPMENT

A dough-mixing control device capable of determining dough gluten development is mounted on a dough mixer and has a controller, a power sensor, a temperature sensor, an output module and an operation module. The controller is electrically connected to the power sensor, temperature sensor, output module and operation module. Each parameter and determination condition inputted through the operation module is transmitted to the controller. A dough gluten development determination procedure built in the controller controls temperature and gluten development of mixed dough and performs statistical calculation according to the inputted parameters and determination conditions so as to acquire the optimal gluten development of dough. Accordingly, drawbacks such as high human production cost and unstable dough quality of conventional dough mixing that relies on human experience to determine dough gluten development can be resolved. 1. A dough-mixing control method capable of determining dough gluten development , comprising:a dough gluten development determination step determining if a moving average ratio of average current or power has reached its maximum where the average current or power is consumed by a dough mixer while mixing a piece of dough, and if positive, further determining that an optimal condition of dough gluten of the piece of dough has been reached; anda statistical production control step recording or calculating an optimal total mixing time and an optimal total mixing energy associated with a dough recipe, wherein the optimal total mixing time is equal to a calculated sum of multiple mixing periods corresponding to multiple mixing speed stages in the dough mixing process, and the optimal total mixing energy is equal to a sum of power consumed in the mixing speed stages in the dough mixing process.7. The method as claimed in claim 1 , whereineach of the optimal total mixing time and the optimal total mixing energy has a range factor serving as a tolerance ...

AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES

A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt. 12. Compound of claim 11 , which is (3R claim 11 ,4s claim 11 ,5S claim 11 ,7s)-1-azaadamantan-4-yl formate.13. Compound of claim 11 , which is (3R claim 11 ,4r claim 11 ,5S claim 11 ,7s)-1-azaadamantan-4-yl formate.14. A process comprising step of contacting (E)-N-(cyclohex-3-en-1-ylmethylene)-1-phenylmethanamine with an isomerizing agent present in an amount ranging from about 0.05 to 0.2 molar equivalents of the isomerizing agent to the (E)-N-(cyclohex-3-en-1-ylmethylene)-1-phenylmethanamine.15. Process of claim 14 , wherein the isomerizing agent is potassium tert-butoxide.16. A process for preparing a 2-amino-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole salt claim 14 , the process comprising step of contacting aminothiourea and benzoic acid in presence of polyphosphoric acid.18. A process for preparing 2-bromo-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole claim 14 , or salt or solvate thereof claim 14 , the process comprising step of contacting a 2-amino-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole salt claim 14 , a Cu(II)halide and an alkyl-nitrite claim 14 , in presence of a polar aprotic solvent.20. A process for preparing 2-bromo-5-phenyl-1 claim 14 ,3 claim 14 ,4-thiadiazole claim 14 , or salt or solvate thereof claim 14 , the process comprising steps of:(a) contacting aminothiourea and benzoic acid in presence of polyphosphoric acid to form a 2-amino-5-phenyl-1,3,4-thiadiazole salt; and(b) contacting the 2-amino-5-phenyl-1,3,4-thiadiazole salt, a Cu(II)halide and an alkyl-nitrite, in presence of ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 1. A compound 4-(4-{[2-(4-chlorophenyl)-4 ,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2 ,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a crystalline form , wherein the crystalline form is Compound 1 free base dichloromethane solvate , characterized by a powder X-ray diffraction pattern having five or more peaks selected from those at 5.9 , 7.1 , 9.6 , 10.0 , 10.7 , 11.1 , 13.2 , 14.8 , and 18.2 degrees 2θ , each peak being ±0.2 degrees 2θ (pattern E) , when measured at about 25° C. with Cu Kradiation at 1.54178 Å.2. The compound of claim 1 , wherein the crystalline form is Compound 1 free base dichloromethane solvate claim 1 , characterized by a monoclinic lattice type and P21/n space group having unit cell lengths for the three axes of about (a) 13.873 Å claim 1 , (b) 12.349 Å claim 1 , (c) 29.996 Å and the three unit cell angles of about (α) 90.00° claim 1 , (β) 92.259° claim 1 , and (γ) 90.00°.3. A pharmaceutical composition comprising the compound of and one or more pharmaceutically acceptable excipients.4. A process for preparing a pharmaceutical solution of Compound 1 comprising dissolving the compound of in a pharmaceutically acceptable solvent or mixture of solvents.5. A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein claim 1 , comprising administering to a subject having the disease a therapeutically effective amount of (a) the compound of or (b) ...

Anti-Infective Agents and Uses Thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 1. A crystalline form of N-(6-(3-tert-butyl-5-(2 ,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide and salts thereof.2. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of a solvate claim 1 , a hydrate and a solvent-free crystalline form.3. The crystalline form of claim 1 , wherein the crystalline form is selected from the group consisting of:crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide acetonitrile solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide ethyl acetate solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide 2-propanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide methanol solvate;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl)methanesulfonamide 1-propanol solvate;crystalline solvent free N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide;crystalline N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl) naphthalen-2-yl) ...

SSD CONTROLLING CIRCUIT FOR DETERMINING REUSABILITY OF DATA BLOCK OF SSD

A SSD controlling circuit includes: a read and write circuit for coupling with a SSD; and a flash memory controlling circuit coupled with the read and write circuit and configured to operably conduct following operations: reading data from a target data block of the SSD and conduct error checking and correction operation on retrieved data; if uncorrectable error occurs, moving data of the target data block to other blocks; erasing the target data block; writing test data into the target data block; after a predetermined time, reading test data from the target data block and conduct error checking and correction operation on retrieved data; recording error counts of the target data block; and determining the reusability of the target data block according to the recorded error counts. 1140100100110120140. A SSD controlling circuit () of a solid state drive device () , wherein the solid state drive device () comprises a SSD () and a communication interface () , the SSD controlling circuit () comprising:{'b': 141', '110, 'a read and write circuit () arranged to operably couple with the SSD (); and'}{'b': 143', '141', '120, 'a flash memory controlling circuit (), coupled with the read and write circuit (), utilized for coupling with the communication interface () and arranged to operably perform following operations{'b': 1', '111', '110', '141, '(A) reading data from a first data block () of the SSD () through the read and write circuit (), and conducting an error checking and correction operation on retrieved data;'}{'b': 1', '1', '111, '(B) if uncorrectable error occurs in the data retrieved in the operation (A), moving data stored in the first data block () to other blocks;'}{'b': 1', '111', '141, '(C) erasing the first data block () through the read and write circuit ();'}{'b': 1', '111', '141, '(D) writing test data into the first data block () through the read and write circuit ();'}{'b': 1', '111', '141, '(E) waiting for a predetermined period of time and then ...

System and Method for Reserving a Parking Space

Provided herein are methods for reserving a parking space. In a user-implemented method, a user inputs a request into an electronic device to reserve one or more parking spaces and pays for the reservation. The reservation may be for a general parking space or for a specific parking space in a parking lot or garage. In another method the user inquiry is received as input and processed on an electronic device networked to a central cloud server comprising a distributed cloud computer system. A status of the parking space is displayed to the user in real time to which the user makes a reply. Also provided is a distributed e-parking space system able to execute instructions to receive input and, via a Distributed Internet Services system, to distribute an application or components to process input, deploy the distributed applications/components and synchronize data related to the reservation process. 1. A user-implemented method for reserving a parking space in a parking lot on an electronic device having at least a processor , a memory and a network connection , comprising the steps of:inputting a request to reserve one or more parking spaces into the electronic device; andpaying for the reservation.2. The user-implemented method of claim 1 , wherein the inputting step comprises:receiving the request for a parking space; anddetermining if parking space is available or unavailable; wherein, if the space is available, outputting the information to the user or wherein, if the space is unavailable, offering to place the user on a waiting list.3. The user-implemented method of claim 2 , wherein the request is for a specific parking space.4. The user-implemented method of claim 1 , wherein the paying step comprises:inputting a period of time in which to arrive at the parking space;paying the fee for the requested reservation time period; andreceiving confirmation of payment received.5. The user-implemented method of claim 1 , wherein the request for the parking space is ...

NOVEL MONOHYDRATE OF AZAADAMANTANE DERIVATIVES

The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound. 2. The crystalline monohydrate of (4s)-4-(5-phenyl-1 claim 1 ,3 claim 1 ,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate of claim 1 , wherein the monohydrate comprises a purity of at least 90% of the monohydrate form and not greater than 10% of the non-monohydrate form.3. The crystalline monohydrate of (4s)-4-(5-phenyl-1 claim 1 ,3 claim 1 ,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate of claim 1 , wherein the monohydrate comprises a purity of at least 95% of the monohydrate form and not greater than 5% of the non-monohydrate form.4. The crystalline monohydrate of (4s)-4-(5-phenyl-1 claim 1 ,3 claim 1 ,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate of claim 1 , wherein the monohydrate comprises a purity of at least 97% of the monohydrate form and not greater than 3% of the non-monohydrate form.5. The crystalline monohydrate of (4s)-4-(5-phenyl-1 claim 1 ,3 claim 1 ,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate of claim 1 , demonstrating at least one characteristic peak in the powder X-ray diffraction pattern at values in degrees two theta of 8.4±0.20 claim 1 , 11.3±0.20 claim 1 , 14.2±0.20 claim 1 , 15.5±0.20 claim 1 , 16.4±0.20 claim 1 , 16.6±0.20 claim 1 , 17.2±0.20 claim 1 , 19.7±0.20 claim 1 , 20.7±0.20 claim 1 , 21.0±020 claim 1 , 21.2±020 claim 1 , 21.6±0.20 claim 1 , 24.8±0.20 claim 1 , and 26.9±0.20.6. The crystalline monohydrate of (4s)-4-(5-phenyl-1 claim 1 ,3 claim 1 ,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.1]decane dihydrogen citrate of claim 1 , having unit cell parameters wherein a is about 6.52 Å claim 1 , b is about 20.99 Å claim 1 , c is about 16.83 Å claim 1 , α is about 90.0° claim 1 , β is about 93.75° claim 1 , γ is about 90.0° ...

SYSTEM AND METHOD FOR ESTIMATING A REMAINING LIFETIME OF AN ALDEHYDE FILTER

A system is for estimating a remaining lifetime of an aldehyde filter. The system comprises aa aldehyde filter () through which at least a portion of the gas is to be passed for removing aldehyde () from the gas () and a detecting medium () through which at least a portion of the gas is to be passed comprising photoluminescent carbon-based dots (), a light source for emitting an excitation light (E) through the detecting medium for exciting the carbon-based dots which thereby emit luminescent light (L), a detector () for detecting the luminescent light (L), the luminescent light (L) having a luminescence property; and a controller () for determining information relating to intensity of a red, a green or a blue component of the luminescence property and estimating a remaining lifetime of the aldehyde filter from the determined information. 1. A system for estimating a remaining lifetime of an aldehyde filter , comprising:an aldehyde filter through which at least a portion of the gas is to be passed for removing aldehyde from a gas;a detecting medium through which at least a portion of the gas is to be passed comprising photoluminescent carbon-based dots;a light source for emitting an excitation light through the detecting medium for exciting the carbon-based dots which thereby emit luminescent light, wherein the emitted luminescent light from the carbon-based dots comprises luminescent properties which change when they are contacted with an aldehyde, wherein the extent of the change is dependent on the amount of an aldehyde that has been adsorbed by the detecting medium;a detector for detecting the luminescent light; anda controller for determining information relating to the luminescence property and estimating a remaining lifetime of the aldehyde filter from the determined information.2. The system according to claim 1 , wherein the gaseous aldehyde is one or more of formaldehyde claim 1 , acetaldehyde claim 1 , propionaldehyde claim 1 , benzaldehyde and ...

A SYSTEM AND METHOD FOR DETERMINING A RISK LEVEL OF A POLLEN-INDUCED ALLERGY OF A USER

The invention provides a system for determining a risk level of a pollen-induced allergy of a user. The system comprises an input for receiving information relating to a pollen level in a location, an input for receiving information relating to a particulate matter level in the location and an input for receiving information relating to a sensitivity of a user to pollen allergen. The system further comprises a processor which is adapted to determine the risk level by taking account of the information relating to a pollen level, the information relating to a particulate matter level and the information relating to a sensitivity of the user to pollen allergen. A user interlace communicates the risk level in the location to the user. 1. A system for determining a risk level of a pollen-induced allergy of a user , comprising:an input for receiving information relating to a pollen level in a location;an input for receiving information relating to a particulate matter level in the location;an input for receiving information relating to a sensitivity of a user to pollen allergen;a processor which is adapted to determine the risk level by taking account of the information relating to a pollen level, the information relating to a particulate matter level and the information relating to a sensitivity of the user to pollen allergen; anda user interface for communicating the risk level in the location to the user.2. The system of claim 1 , comprising a pollen sensor for generating the information relating to the pollen level in the location.3. The system of claim 1 , comprising a particle sensor for generating the information relating to a particulate matter level in the location.4. The system of claim 1 , comprising a breathing sensor for determining a breathing rate of the user claim 1 , and wherein the processor is further adapted to take account of the breathing rate in determining the risk level.5. The system of claim 1 , comprising a further input for receiving ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 116.-. (canceled)17. A method for treating a hematopoietic malignancy in a human patient , comprising:orally administering to the human patient a solid dosage form prepared by dissolving a free base crystalline form of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a pharmaceutically acceptable solvent or mixture of solvents in an amount sufficient to deliver a therapeutically effective amount of Compound 1 to the human patient.18. The method of claim 17 , wherein the hematopoietic malignancy is a lymphoid malignancy.19. The method of claim 18 , wherein the lymphoid malignancy is chronic lymphocytic leukemia.20. The method of claim 17 , wherein the therapeutically effective amount is 100 mg of Compound 1. This application is a divisional application of U.S. application Ser. No. 15/806,964 (published as U.S. Pub. No. 2018/0065961), filed Nov. 8, 2017, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 15/806,964 is a continuation of U.S. application Ser. No. 14/957,097 (issued as U.S. Pat. No. 9,840,502 B2), filed Dec. 2, 2015, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 14/957,097 is a divisional application of U.S. application Ser. No. 14/228,132 (issued as U.S. Pat. No. 9,238,649 B2), filed Mar. 27, 2014, which is hereby incorporated by reference as if set forth ...

PARTICLE OR POLLEN SENSOR AND SENSING METHOD

A particle or pollen sensor comprises an array of relative humidity sensors. A change in relative humidity is representative of a particle or pollen in contact with one or more of the sensors. A size and/or shape of a particle or pollen in contact with one or more of the sensors is optionally also determined based on the number and/or configuration of sensors. From this information, a particle or pollen type is determined. 1. A particle or pollen sensor comprising:an array of relative humidity sensors; anda processor for processing the signals from the array of humidity sensors,wherein the processor is adapted to:detect a change in relative humidity representative of a particle or pollen in contact with one or more sensors of the array of relative humidity sensors, and thereby determine a change in relative humidity associated with presence of the particle or pollen; andidentify a type of a particle or pollen based on the change in relative humidity.2. The particle or pollen sensor as claimed in claim 1 , wherein the processor is further adapted to:detect a size and/or shape of a particle or pollen in contact with one or more of the sensors based on the number and/or configuration of sensors; andidentify a particle or pollen type additionally based on the size and/or shape.3. The particle or pollen sensor as claimed in claim 1 , further comprising a fan for drawing air to the array of relative humidity sensors.4. The particle or pollen sensor as claimed in claim 1 , further comprising a vibrator for dislodging particles or pollen from the array of relative humidity sensors.5. The particle or pollen sensor as claimed in claim 4 , wherein the vibrator comprises a piezoelectric vibrator attached to the array of relative humidity sensors.6. The particle or pollen sensor as claimed in claim 1 , wherein the array of relative humidity sensors comprises an array of polymer elements and an array of readout conductors claim 1 , and a detection circuit for monitoring impedance ...

HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOF

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition. 2. The method of claim 1 , wherein said non-aqueous low boiling solvent comprises Hydrofluoroether CFOCH.3. The method of claim 2 , wherein said non-aqueous low boiling solvent comprises HFE7100.4. The method of claim 1 , wherein said suspension further comprises Lysine or Tris.5. The method of claim 1 , wherein said suspension further comprises calcium chloride.6. The method of claim 1 , wherein said water is added in a quantity preventing full clotting of fibrinogen.7. The method of claim 1 , wherein said water is added in a quantity resulting in less than 50% of fibrinogen conversion into fibrin.8. A method of treating a wound by applying the hemostatic composition formed by method of onto and/or into the wound.9. A method of treating an air leak in a lung by applying the hemostatic composition formed by method of onto and/or into the lung. The present invention relates generally to agents and materials for promoting hemostasis and tissue sealing and, more particularly, to resorbable hemostatic particulates with improved efficacy, particularly particulate aggregates made of fibrinogen, thrombin, and oxidized regenerated cellulose, and to methods for manufacturing such compositions.In a wide variety of circumstances, animals, including humans, can suffer from bleeding due to wounds or during surgical procedures. In some circumstances, the bleeding is ...

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

HUMIDITY ADJUSTMENT

Embodiments of the present invention relate to humidity adjustment. In some embodiments, a humidity adjustment device is provided. The humidity adjustment device comprises a container including a wall for defining an accommodating space. The wall includes a water separating element for separating a mixture of water vapor and liquid water, wherein the water separating element includes a sieve portion adapted to separate the mixture of water vapor and liquid water, characterized in that the sieve portion comprises holes whose sizes are in the range of 25-35 microns. Corresponding apparatus and method are disclosed as well. 1. A humidity adjustment device , comprising:a container including a wall for defining an accommodating space,the wall including a water separating element for separating a mixture of water vapor and liquid water, wherein the water separating element includes a sieve portion adapted to separate the mixture of water vapor and liquid water, wherein the sieve portion comprises holes whose sizes are in the range of 25-35 microns.2. The device according to claim 1 , wherein the container includes a supporting structure adapted to support the sieve portion.3. The device according to claim 1 , wherein the wall is entirely formed by the sieve portion.4. The device according to claim 1 , wherein the sieve portion comprises a coating comprising superhydrophobic material.5. The device according to claim 1 , wherein the container further includes a bottom adapted to drain away droplets formed in the container.6. The device according to claim 5 , wherein the bottom is perforated or grooved.7. An apparatus claim 1 , comprising a humidity adjustment device according to any of claim 1 , further comprising a mist generator for generating the mixture of water vapor and liquid water.8. The apparatus according to claim 7 , wherein the mist generator is outside of the container.9. The apparatus according to claim 7 , wherein the mist generator is inside of the container ...

Crystal Forms

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. - 1. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern at values of two theta as described in any one of Tables 1a , 2a , 3a , and 4a.2. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern as described in any one of .3. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern as described in the specification.4. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern at values of two theta (° 2θ) of 8.4 , 8.9 , 11.1 , 12.2 , 14.5 , 15 , 15.9 , 17.4 , 17.8 , and 22.2.5. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern at values of two theta (° 2θ) of 8.4 , 8.9 , 10.2 , 11.1 , 12.2 , 12.5 , 13.2 , 13.7 , 14.5 , 15 , 15.5 , 15.9 , 17.4 , 17.8 , 19.6 , 19.9 , 21.1 , 22.2 , 22.7 , and 23.9.6. A crystalline form of Compound I , wherein said crystalline form has characteristic peaks in PXRD pattern at values of two theta (° 2θ) of 6.7 , 8.4 , 8.9 , 9.9 , 10.2 , 11.1 , 12.2 , 12.5 , 13.2 , 13.7 , 14.5 , 15 , 15.5 , 15.9 , 17.4 , 17.8 , 18.1 , 18.9 , 19 , 19.6 , 19.9 , 21.1 , 21.8 , 22.2 , 22.7 , 22.8 , 23.2 , 23.9 , 24.6 , and 25.1.7. A composition claim 1 , comprising a crystalline form according to .8. A process for making a pharmaceutical composition comprising Compound I claim 1 , comprising dissolving a crystalline form according to .9. A composition claim 2 , comprising a crystalline form according to .10. A composition claim 3 , comprising a crystalline form according to .11. A composition claim 4 , comprising a crystalline form according to .12. A composition claim 5 , comprising a crystalline form according to .13. A ...

METHOD AND DEVICE FOR MEASURING OPTICAL SIGNAL-TO-NOISE RATIO

Embodiments of the present invention relate to method and device for measuring optical signal-to-noise ratio (OSNR). A method for measuring an OSNR of a signal of interest may comprise: obtaining spectrum of the signal of interest, the spectrum including power spectrum density distribution of the signal of interest in a channel bandwidth B; obtaining spectrum of a comparative signal that has the same spectrum characteristics as but different OSNR than the signal of interest, the spectrum including power spectrum density distribution of the comparative signal in the channel bandwidth B; and calculating the OSNR of the signal of interest by using the spectrum of the signal of interest and the spectrum of a comparative signal. 1. A method for measuring an optical signal-to-noise ratio (OSNR) of a signal of interest , comprising:obtaining spectrum of the signal of interest, the spectrum including power spectrum density distribution of the signal of interest in a channel bandwidth B;obtaining spectrum of a comparative signal that has the same spectrum characteristics as but different OSNR than the signal of interest, the spectrum including power spectrum density distribution of the comparative signal in the channel bandwidth B; andcalculating the OSNR of the signal of interest by using the spectrum of the signal of interest and the spectrum of a comparative signal.2. The method of wherein the signal of interest and the comparative signal are obtained from different points in the same optical transmission line.3. The method of wherein the comparative signal is an optical signal obtained by processing the signal of interest to change its OSNR.4. The method of wherein the comparative signal is an optical signal obtained from an optical transmission line different from that of the signal of interest claim 1 , generated from the same light source as the signal of interest claim 1 , and having the same modulation format as the signal of interest.5. The method of wherein the ...

SENSOR AND COMBINED MAGNETIC NAVIGATION SENSOR

A magnetic stripe sensor adaptable for different automated guided vehicles and with enhanced precision of guidance includes a main body, a plurality of first assembly members, and a plurality of second assembly members. The first assembly members and the second assembly members are respectively fixed to a first and a second surface of the main body. Each assembly member defines a slot, and each second assembly member includes a guiding block. The size and shape of the guiding block matches those of the slot, allowing combinations of first and second assembly members as desired. A combined magnetic navigation sensor assembled from first and second assembly members is also disclosed. 1. A sensor comprising a main body , a plurality of first assembly members , and a plurality of second assembly members , wherein the main body comprises a first surface and a second surface opposite to the first surface , the first assembly members and the second assembly members are respectively fixed to the first surface and the second surface , each of the first assembly members defines a slot , and each of the second assembly members comprises a guiding block , the guiding block having a shape and a size matching with a shape and a size of the slot correspondingly.2. The sensor according to claim 1 , wherein the plurality of first assembly members are fixed side by side on the first surface.3. The sensor according to claim 1 , wherein the plurality of second assembly members are fixed side by side on the second surface.4. The sensor according to claim 1 , wherein the slot is defined on each of the first assembly member away from the first surface claim 1 , each of the second assembly member further comprises a fixing plate claim 1 , the fixing plate is fixed to the second surface claim 1 , and the guiding block is formed on the fixing plate away from the second surface.5. The sensor according to claim 1 , wherein the slot is a dovetail slot claim 1 , and the guiding block is a ...

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. 1. Solid amorphous 4-(4-{[2-(4-chlorophenyl)-4 ,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2 ,3-b]pyridin-5-yloxy)benzamide (Compound 1).2. A process for preparing a pharmaceutical formulation comprising combining the solid amorphous Compound 1 of with a pharmaceutically acceptable excipient. This application is a continuation application of U.S. application Ser. No. 15/806,964 (published as U.S. Pub. No. 2018/0065961), filed Nov. 8, 2017, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 15/806,964 is a continuation of U.S. application Ser. No. 14/957,097 (issued as U.S. Pat. No. 9,840,502 B2), filed Dec. 2, 2015, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 14/957,097 is a divisional application of U.S. application Ser. No. 14/228,132 (issued as U.S. Pat. No. 9,238,649 B2), filed Mar. 27, 2014, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 14/228,132 is a continuation application of U.S. application Ser. No. 13/301,257 (issued as U.S. Pat. No. 8,722,657 B2), filed Nov. 21, 2011, which is hereby incorporated by reference as if set forth in its entirety. U.S. application Ser. No. 13/301,257 claims the benefit of U.S. provisional application Ser. No. 61/416,656, filed Nov. 23, 2010, which is hereby incorporated by reference as if set forth in its entirety.Cross-reference is also ...

PORTABLE POWER BANK

A portable power bank includes a main body, a charging slot, a back plate, and a charging module. The charging slot is at the back surface of the main body. The charging slot has an accommodating space for receiving an electronic product. The back plate is pivotally connected to the back surface and is movable between a first position and a second position. A first angle is between the back plate at the first position and the back surface, and the back plate at the second position is received on the back surface. The output terminal of the charging module is at the surrounding wall for charging the electronic product. The conversion circuit of the charging module is for converting electricity from the input terminal and outputting to the battery or the output terminal, and converting electricity stored in the battery and outputting to the output terminal. 1. A portable power bank , comprising:a main body having a front surface, a back surface opposite to the front surface, and a side surface connected to the front surface and the back surface;a charging slot capable of receiving an electronic product, wherein the charging slot is at the back surface; the charging slot has a surrounding wall, the surrounding wall is recessed inwardly, and an accommodating space is defined by the surrounding wall;a back plate pivotally connected to an upper edge of the back surface, wherein the back plate is movable between a first position and a second position; when the back plate is at the first position, a first angle is between the back plate and the back surface of the main body; when the back plate is at the second position, the back plate is received on the back surface; and a battery;', 'an input terminal exposed from the main body;', 'an output terminal at the surrounding wall; and', 'a conversion circuit electrically connected to the battery, the input terminal, and the output terminal, wherein the conversion circuit is capable of converting received electricity from the ...

PARTICLE CHARACTERIZATION APPARATUS AND METHOD

An apparatus is provided for determining particle characteristics, in which a flow path is generated containing particles to be analyzed. A light detection system detecting light received from a measurement zone which has been scattered by the particles. A time duration for which a particle remains in the measurement zone is measured to determine an effective aerodynamic particle diameter and a peak detected received light intensity is measured to determine an effective optical particle diameter. A further particle parameter is also obtained relating to the shape and/or density of the particle. This approach enables more information than only a particle size to be obtained using a single-stage optical analysis system. The additional information may be used to characterize the particles more accurately. 1. An apparatus for determining particle characteristics , comprising:an inlet and an outlet;a flow system for generating a flow path between the inlet and the outlet along which an accelerating flow is to be provided containing particles to be analyzed;a light source for providing light to the flow path, wherein the envelope of the light defines a measurement zone, the measurement zone having a length of more than 1 cm;a light detector for detecting light received from the measurement zone which has been scattered by the particles; anda controller for analyzing the detected received light, determine a time duration for which a particle remains in the measurement zone, and thereby determine an effective aerodynamic particle diameter;', 'determine a peak detected received light intensity and thereby determine an effective optical particle diameter;', 'determine a further particle parameter relating to the shape and/or density of the particle., 'wherein the controller is adapted to2. An apparatus as claimed in claim 1 , wherein the controller is adapted to:determine the further particle parameter as a ratio between a particle shape parameter and a particle density.3. An ...

TWO-DIMENSIONAL CODE IDENTIFICATION AND POSITIONING

The present specification provides a two-dimensional code identification method and device, and a two-dimensional code positioning and identification model establishment method and device. The two-dimensional code identification method includes: obtaining a to-be-identified two-dimensional code, and performing global feature positioning detection on the to-be-identified two-dimensional code by using a pre-established two-dimensional code positioning and identification model; performing focus adjustment, based on a predetermined image resolution, on the to-be-identified two-dimensional code on which positioning detection is performed; and decoding the to-be-identified two-dimensional code on which focus adjustment is performed. The present specification can improve the identification accuracy of two-dimensional codes shot in complex scenarios. 1. A computer-implemented method , comprising:obtaining an image of a two-dimensional code;detecting the two-dimensional code within the image by performing global feature positioning detection using a pre-established two-dimensional code positioning and identification model;subsequent to detecting the two-dimensional code, obtaining a focus-adjusted image of the two-dimensional code based on a predetermined image resolution; anddecoding the two-dimensional code from the focus-adjusted image of the two-dimensional code.2. The computer-implemented method of claim 1 , wherein the method comprises:determining that a resolution of the image of the two-dimensional code fails to satisfy the predetermined image resolution; and obtaining the focus-adjusted image of the two-dimensional code based on the predetermined image resolution responsive to determining that the resolution of the two-dimensional code fails to satisfy the predetermined image resolution.3. The computer-implemented method of claim 1 , wherein obtaining the focus-adjusted image of the two-dimensional code based on the predetermined image resolution comprises applying ...

Service Level Adjustment Method, Apparatus, Device, and System, and Storage Medium

This application discloses a service level adjustment method, apparatus, device, and system, and a storage medium. The method includes: A control device obtains at least one piece of related information in at least one piece of queue status information, a remaining data flow parameter, a current data flow parameter, and a quantity of reporting times of exception information of a target service level of a network device. The control device adjusts, when any information in the related information does not meet a threshold corresponding to the any information, a parameter of the target service level based on a maximum delay associated with the target service level. 1. A method , comprising:obtaining, by a control device, related information of a target service level of a first network device, wherein the related information of the target service level comprises: at least one piece of queue status information of the target service level, a remaining data flow parameter of the target service level, a current data flow parameter of the target service level, or a quantity of reporting times of exception information of the target service level; andadjusting, by the control device when any information in the related information does not meet a threshold corresponding to the respective any information, a parameter of the target service level based on a maximum delay associated with the target service level.2. The method according to claim 1 , wherein the related information comprises the at least one piece of queue status information of the target service level; and 'adjusting, by the control device when any piece of the at least one piece of queue status information is less than a threshold lower limit corresponding to the respective any piece of queue status information, the parameter of the target service level based on the maximum delay associated with the target service level.', 'wherein adjusting, by the control device when any information in the related information ...

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Crystalline forms of rapamycin analogs.

Una composición de análogo de rapamicina incluye una forma cristalina de un análogo de rapamicina. El cristal puede ser un hidrato, dehidrato, solvato, o desolvato. El análogo de rapamicina puede tener una estructura de la Fórmula (I), el cual es opcionalmente un profármaco, sal, derivado, o combinación de los mismos: Fórmula (I).

Methods of manufacturing crystalline forms of rapamycin analogs

A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

Salts and crystalline forms of an apoptosis-inducing agent

Disclosed are salts and crystalline forms of the compound 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (abstract figure). The crystalline forms include anhydrates, hydrates, dichloromethane solvate, ethyl acetate solvate, acetonitrile solvate, acetone and tetrahydrofuran. The salts include hydrochloride and sulfate. The disclosure also relates to pharmaceutical compositions comprising the salts and crystalline forms and methods for treating diseases characterised by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein by using the salts and crystalline forms herein.

N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors.

Esta invención se relaciona con: (a) compuestos y sales de los mismos que, entre otros, inhiben el HCV; (b) intermediarios de utilidad para la preparación de dichos compuestos y sales; (c) composiciones que comprenden dichos compuestos y sales; (d) métodos para preparar dichos intermediarios, compuestos, sales y composiciones; (e) métodos de uso de dichos compuestos, sales y composiciones; y (f) conjuntos de elementos que comprenden dichos compuestos, sales y composiciones. Los compuestos son útiles en el tratamiento de hepatitis C y tienen la siguiente estructura general: Formula (1).

Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands

Anti-infective agents and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

A system and method for determining a risk level of a pollen-induced allergy of a user

Anti-infectious pyrimidines and their applications

URACYL OR THYMIN DERIVATIVE TO TREAT HEPATITIS C

Crystal forms

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1 - 4.

Method and system for deploying an asset over a multi-tiered network

A method for distributing changes to digital assets across a network includes determining an asset type of a first digital asset and comparing the first digital asset to a prior digital asset to determine one or more deltas, the prior digital asset being a prior version of the first digital asset and the delta being a difference between the first digital asset and the prior digital asset. The method further includes evaluating the one or more of the deltas with one or more criteria to determine if the one or more delta assets should be created, the delta asset being a second digital asset containing the respective delta, the criteria determined by the asset type. The method further includes that if the delta meets the criteria, creating the delta asset, and marking the delta asset as a first delta asset of the first digital asset.

Anti-infective pyrimidines and uses thereof

Anti-infective pyrimidines and uses thereof

System, method, uses, products, program products, and business methods for distributed internet and distributed network services

A component distribution server (CDS) system (1100) connected to at least one network (1110) through at least one respective network interface includes: a package specification process that receives at least one package, the packages being subparts of at least one application program from at least one enterprise information system EIS (1120), the packages having at least one assets, each asset having an asset type and at least two asset layers, a first asset layer being a logic/data layer and a second asset layer being an extended environment layer, the logic/data layer having information that includes a function of the asset and the extended environment layer being a subset of the EIS and having portions of the EIS necessary to support the respective logic/data layer; a process adapter process that translates at least one of the assets layers so that the asset performs the asset function on at least one target base environment of at least one target computer (1150); and a target process that changes the at least one of the layers of the asset in order to provide specific information for at least one of the specific target computers, whereby a transformed asset is an asset that is translated by the process adapter process and changed by the target process.

System and method for bridging assets to network nodes on multi-tiered networks

An exemplary method and/or exemplary embodiment of the present invention provides a system and method for bridging an asset over a multi-tiered network. An asset may represent network and/or application components (e.g., data, objects, applications, program modules, etc.) that may be distributed among the various resources of the network. Generally, communications can be maintained between executable assets residing on different network nodes by bridging the execution context of the two nodes. In an embodiment, a mapping layer can be generated for assets that have run-time dependencies; the mapping layer uses a distribution system to bridge the execution context of a first environment with that of a second environment. The asset executing in the first environment is able to access another resource located in the second environment, even though the asset does not have local access to the resource in the second environment. A fault is detected when at least one asset deployed on a local node attempts to access at least one resource on a remote node through an application programming interface. The fault is then be handled appropriately.

Anti-infective pyrimidines and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

System and method for detection of a gaseous aldehyde

The present invention relates to a system (10) for detection of a gaseous aldehyde (34). The system (10) comprises a container (20) having a carrier medium (22), the carrier medium having dispersed carbon element based dots (24) with photoluminescence property; an air inlet (30) for guiding a gas flow (32) comprising the gaseous aldehyde to pass through the carrier medium (22); a light source (40) for emitting an excitation light (E) and for guiding the excitation light (E) through the carrier medium (22); a detector (50) for detecting luminescent light (L) triggered by the excitation light (E), the luminescent light (L) having a luminescence property; and a controller (60) for detecting concentration of the gaseous aldehyde (34) based on a change of the luminescence property.

Particle sensor and sensing method

A particle or pollen sensing method in which a relative humidity is controlled in a particle treatment region and the particle size is determined before and after humidity treatment. A particle type is then identified based on particle property changes such as size, electrical properties or optical properties, caused by the humidity treatment.

Secure computer-implemented execution and evaluation of programming assignments for on demand courses

In one general aspect, a computer-implemented method can include receiving, by a computer system, code for a custom grader application, creating, by the computer system, a base custom grader container including the code for the custom grader application, associating the base custom grader container with an online course included in a repository included in the computer system, evaluating, by the computer system, the base custom grader container by executing the custom grader application in the base custom grader container, determining that the custom grader application violates a predetermined criterion, modifying the base custom grader container to prevent the executing of the custom grader application from violating the predetermined criterion, and storing, in the repository and in association with the online course, the modified base custom grader container including the custom grader application as a custom grader container image.

Crystal forms of hcv protease inhibitors and use thereof

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4.

Air purifier including air filter life-time indicator and method for determining the life-time of an air filter

Anti-infective pyrimidines and uses thereof

This invention relates to: (a) compounds and salts thereof that, inter alia , inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

AZA-ADAMANTAN DERIVATIVE COMPOUNDS, ITS USES AND PROCESSES FOR THE PREPARATION OF THESE COMPOUNDS

resumo “compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos” a invenção refere-se a mono-hidrato cristalino de citrato dihidrogenado de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-ilóxi)-1-azatriciclo[3,3,1,13,7]decano, composições compreendendo tal composto, e um processo para a preparação de tal composto. Summary "Compounds Derived From Aza-Adamantane, Their Uses and Processes for the Preparation of These Compounds" The invention relates to (4s) -4- (5-phenyl-1,3,4-dihydrogenated citrate crystalline monohydrate) thiadiazol-2-yloxy) -1-azatricyclo [3,3,1,13,7] decane, compositions comprising such a compound, and a process for the preparation of such a compound.

Ozone disinfection linkage device for clean area

一种洁净区臭氧消毒联动装置，包括主控芯片，所述主控芯片的型号为STM32F103，在主控芯片上设有多个输入引脚和输出引脚，所述主控芯片通过输出引脚连接有臭氧发生器和空调净化器，在臭氧发生器上设有与臭氧发生器配合设置的浓度传感器，在空调净化器上设有与空调净化器配合设置的开度传感器，所述浓度传感器和开度传感器分别通过输入引脚连接到主控芯片上，所述主控芯片通过输入引脚还连接有时钟模块和看门狗模块，所述时钟模块用于记录臭氧发生器的消毒时间，所述看门狗模块用于保持主控芯片稳定运行，在主控芯片内设有电气相连的比较器模块和AD转换模块。

System, method, uses, products, program products, and business methods for distributed internet and distributed network services

A method and system for functioning within the field of distributing networks, web and server applications, systems, subsystems, applications, sub-applications, components, modules, functions, over one or more computer networks. A method and system for deploying and/or adjusting and/or transmitting and/or receiving digital assets and otherwise in a multi-tiered network.

Crystalline forms of rapamycin analogs

Salts and crystalline forms of an apoptosis-inducing agent.

Las sales y formas cristalinas de 4-(4-{[2-(4-clorofenil)-4,4-dime tilciclohex-1 -en-1-iI]metíl}piperazin-1-il)-N-({3-nitro-4-[(tetra hidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirrolo[2,3- b]piridin-5-iloxi)benzamida son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas anti-apoptóticas de la familia de Bcl-2, por ejemplo cáncer.

Mass-Production Comprehensive Vinasse Treatment Process And System

A mass-production comprehensive vinasse treatment system includes a vinasse conveying system, a vinasse washing system, a vinasse liquid utilization and circulation system, and a cleaned vinasse treatment system. The vinasse conveying system includes 5 a feeder and an inclined conveyor belt. An inlet and an outlet of the inclined conveyor belt are provided at an outlet of the feeder and an inlet of a centrifugal washing device respectively. The vinasse washing system includes the centrifugal washing device and multiple cascaded spiral blade solid-liquid separation devices for heavy materials each provided with a spiral blade separator, a high-pressure water spraying port, and a liquid drain 10 valve connected to a vinasse liquid conveying pipe. The cleaned vinasse treatment system includes a belt filter press, a drying machine, and a crushing and grinding machine.